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Abstract

Emergence of antibiotic resistance severely threatens the existing medication and
prevention facilities against an over increasing range of infections caused by a wide range of
microbes. Specifically, treatment of Gram-negative bacterial infection is getting more problematic
due to their resilience against β-lactam antibiotics: the most commonly prescribed antibiotics in
clinical settings. Production of β-lactamases is the most prevalent mechanism utilized by various
Gram-negative pathogens to become resistant to the β-lactam antibiotics e.g, penicillins,
cephalosporins, carbapenems and monobactams. These enzymes mediate their function through
hydrolyzing the core β-lactam ring present in all β-lactam antibiotics which causes opening of the
ring and renders the antibiotics ineffective. β-lactamases are mostly divided into four classes:
Class A, C, D are serine enzymes which require an active site serine and class B are metallo
enzymes harboring either one or two zinc ions to carry out their catalytic function. Classical βlactamase inhibitors (e.g., clavulanate, sulbactam, and tazobactam) exert their action by a covalent
modification of the enzyme, which renders them inactive. However, these inhibitors share the same
chemical structure as β-lactam antibiotics making them susceptible to β-lactamase degradation.
Moreover, the situation becomes even more worrisome due to the emergence of carbapenemases,
which are β-lactamases that degrade carbapenems, the last line of therapeutics in treating MDR
bacterial infections. Recent development of non β-lactam based β-lactamase inhibitors e.g.,
avibactam, vaborbactam and cyclic boronates targeting serine and metallo carbapenemases
provides a proof of potential advancement in the field of drug discovery targeting antibiotic
ix

resistance. However, more investigation is necessary in developing novel inhibitors targeting
multiple β-lactamases in a noncovalent fashion based on their similar substrate recognition
properties and active site commonality. The ultimate goal of this research was to utilize FBDD
and SBDD approach to identify and optimize noncovalent inhibitors through molecular docking,
X-ray crystallography, biochemical and microbiological assessment. This project was also focused
on unraveling the structural basis of carbapenemase activity of OXA-48 class D β-lactamase using
X-ray crystallography.
The first project was about to understand the molecular basis of difference in substrate
profiling between ESBLs e.g. CTX-M-14 and carbapenemases e.g. KPC-2, NDM-1. For this, the
ligand binding properties of CTX-M-14 and KPC-2 have been analyzed using some novel small
tetrazole based molecules obtained from molecular docking. Both CTX-M-14 and KPC-2 belong
to serine β-lactamases and have higher similarity in their active site configuration. Biochemical
analysis showed that inhibitory potency for both β-lactam hydrolyzed product and tetrazole based
inhibitors is ~ 5-fold or higher for KPC-2 compared to CTX-M-14. Based on complex crystal
structures, we hypothesized that KPC-2 active site is more hydrophobic and flexible in nature than
CTX-M-14 which might facilitate its interaction with a wide range of substrates and small
molecule ligand. Both biochemical and structural properties of NDM-1 for these small tetrazole
based molecules proved that hydrophobicity and flexibility in the active site is even more
prominent for NDM-1 MBLs. Taken together, these data suggest that carbapenemase activity
provides an evolutionary advantage on producers to accommodate a wide range of β-lactam
substrates, but also exhibits their mechanistic vulnerability which could be utilized for designing
and development of new inhibitors against them. In addition, this study also emphasized the

x

potential of tetrazole based compounds as well as hydrolyzed β-lactam product for broad-spectrum
inhibitor discovery targeting both serine and metallo carbapenemases.
The second project focused on optimization of a heteroaryl phosphonate scaffold to
improve its potency against KPC-2, NDM-1 and VIM-2 carbapenemases as well as analyzing the
influence of pH in binding of this phosphonate scaffold and analogs in the active site of NDM-1
and VIM-2 MBLs. Several substitutions and optimization of parent phosphonate scaffold led to
the development of a potent lead compound (compound 16) which showed 20 nM and 300 nM
affinity for KPC-2 and VIM-2 as well as 30 µM potency for NDM-1. Complex structures
determined for NDM-1 and VIM-2 at low (pH 4.6) and physiological pH (pH 7.5) exhibits the
difference in the protonation state of phosphonate group of the scaffold. At pH 4.6, phosphonate
group is in a protonated monoanionic state and interacts with both zinc ion by replacing hydroxide
ion. However, at physiological pH (pH 7.5), the phosphonate group is present in its di-anionic state
and interacts with one of the two zinc ions, while retaining the hydroxide ion in the active site of
NDM-1 and VIM-2. Checkerboard assay showed that compound 16 restored imipenem efficacy
against some clinically relevant and laboratory strains harboring KPC-2, NDM-1 and VIM-2.
Overall, these data provide a new phosphonate-based scaffold as a dual inhibitor against serine
and metallo carbapenemase producing gram-negative pathogens.
The third project involved revealing the structural basis of OXA-48 substrate specificity
towards imipenem over other carbapenem and cephalosporin antibiotics. Six complex crystal
structures of OXA-48 has been solved; of which five of them are acyl-enzyme complex with
imipenem (2.0 Å), meropenem (1.9 Å), faropenem (2.1 Å), cefotaxime (2.0 Å) and cefoxitin (2.2
Å). OXA-48 complex structure with hydrolyzed imipenem was also obtained which is the first
product complex structure for any class D β-lactamase where the newly generated carboxylate
xi

group still retain in the oxyanion hole. Lys73 is found to be decarbamylated for all acyl-enzyme
complex structure except for the product complex where carbamylated Lys73 has been observed.
Comparison of product complex with acyl enzyme intermediates reveal the structural basis of
OXA-48 substrate specificity as well as the placement of side chain groups to prevent the access
of hydrolytic water molecule to carry out the deacylation step of the reaction mechanism. This will
further aid in inhibitor discovery against OXA-48 β-lactamase.
The fourth project was mostly focused on screening of fragments and lead like compound
targeting CTX-M-14, KPC-2, NDM-1 and OXA-48. Molecular docking and surface plasmon
reason have been used as a primary screening method to identify potential fragment hits. Most of
the selected hits contain either tetrazole, phosphonate or carboxylate as a functional group in their
structure. These compounds were then subjected to a secondary screening method using a βlactamase assay and their IC 50 values have been determined for all four enzymes. Among the
several different hits obtained, one tetrazole based fragment has micromolar affinity for KPC-2,
NDM-1 and OXA-48 and crystal complex structures were determined for all four enzymes. Most
of the tetrazole compounds have higher affinity for NDM-1 of which one of them has a Ki of 18
µM. Crystal structures showed that tetrazole ring interacts with one of the two zinc ions.
Carboxylate group containing fragments obtained from SPR screening exhibit greater affinity
when tested through biochemical assay. However, more structures are needed to elucidate the
binding properties and structure activity relationship studies for high affinity fragments and lead
like hits. Taken together, these data provide information about some new chemical scaffolds for
future optimization and broad-spectrum inhibitor discovery targeting multiple classes of βlactamases.

xii

Chapter 1: Introduction

1.1 Antibiotic revolution and resistance arrival:
The most prominent reason of morbidity and mortality in the 20th century was due to infectious
diseases, mostly caused by pathogenic bacteria.1 The pathogenicity of these infectious agents was
first described in the late 19th century by Louis Pasteur and Robert Koch through their germ
theory2, which invigorated researchers to look for potential therapeutic arsenals against them. This
drive towards the discovery and development of antibiotics which revolutionized the medicinal
field as well as human history in numerous aspects. The term antibiotics was first proposed by
Selman Waksman, which denotes “opposing life” substance used to treat to or prevent the growth
of pathogenic microorganisms.3 The genesis of antibiotics is associated with the idea of Paul
Ehrlich’s and Sahachiro Hata’s “magic bullet” organometallic compound to treat syphilis in 1910
and the discovery of penicillin by Alexander Fleming in 1928. 4-5 Production of these antibiotics
in large scale saved millions of lives in World War II.6 Since then, many different synthetic and
semi-synthetic analogs of these antibiotics have been developed, owing to the need of new
antibiotics in health care treatment. Most of the antibiotics in the market today were originally
isolated by screening soil-derived actinomycetes during the golden era of antibiotic discovery in
the 1940s to 1960s.7 This successful form of chemotherapy provides a crucial contribution in
improving life expectancy and lowering the childhood morbidity.
To be effective, antibiotics should selectively target bacteria for elimination rather than
impacting host cells. Antibiotics exert their action by impeding a variety of bacterial cellular
1

processes (e.g., disrupting cell wall synthesis and metabolic pathways, preventing DNA/RNA
replication, and protein synthesis).8-11 Antibiotics should also be effective for a wide range of
bacterial pathogens, be able to penetrate to the site of targeted infection, and retain significant
activity without being metabolized to a toxic intermediate that can hamper the host defense
mechanism.12 In addition, antibiotics also need to be produced on a large scale to make their
production cost effective.
Immediately after the introduction of penicillin in the 1940’s, many different synthetic and
semi-synthetic antibiotics were generated.13 However, resistance to several different antibiotics
was observed overtime due to the genetic plasticity and associated environmental adaptation
process present in different pathogens.14-15 The rapid increase in antimicrobial resistance
jeopardizes the accomplishments achieved during the golden age of antibiotic discovery.
According to the World Health Organization (WHO), antibiotic resistance is designated as one of
three most significant public health threats of the 21st century.16 According to the Centers for
Disease Control and Prevention (CDC), around 3 million people in the USA contract an infection
caused by multi-drug resistant (MDR) bacteria, which results in the death of about 35,900 people
every year.17 In addition to an increase in mortality rate, antibiotic resistance also results in a
significant economic burden, estimated at over 20 billion dollars per year in the USA.18 Recent
reports also suggests that antibiotic resistance is estimated to cause around 300 million premature
deaths by 2050, with a loss of up to $100 trillion to the global economy.19 Specifically, the
treatment of Gram-negative bacterial pathogens (e.g., Escherichia coli, Acinetobacter baumannii,
Pseudomonas aeruginosa, Klebsiella pneumoniae, and Neisseria gonorrhoeae) is becoming more
problematic due to their resistance to most, or all, available antibiotics. 20

2

1.2 Mechanism of antibiotic resistance
Antibiotic resistance denotes the capability of microbes to withstand and even carryout
physiological and reproductive function in presence of antibiotic doses which were normally lethal
to them. Due to enormous production and usage of antibiotics in an irresponsible manner,
antibiotic resistance has been observed within 20 years after their introduction into the medicinal
fiel.

21

Throughout evolution, microorganism harbor numerous mechanisms to make themselves

recalcitrant against these wonder drugs. Bacterial antibiotic resistance mechanisms can be intrinsic
or acquired through mutation in the chromosomal genes or transfer of mobile of genetic elements
responsible for resistance.22-23 Intrinsic resistance mechanism denotes the capability of
microorganism to utilize their genetic and functional properties to defy the inhibitory function of
antibiotics. Examples of intrinsic resistance mechanisms used by Gram-negative bacteria include
the reduction of permeability of antibiotics due to the presence of an outer membrane as a
permeability barrier, mutations in the porin channel or substitution of porin channels with more
particular channels, and the presence of MDR efflux pumps to transport antibiotics out of the cell.
24-26

Acquisition of resistance across different microorganisms can also be mediated by several

ways, which include overexpression of efflux pumps or reduction of intracellular antibiotic
concentration due to decreased drug penetration, destruction or modification of antibiotics through
hydrolysis or addition of a chemical group, and/or alteration of the genetic material associated
with the antibiotic target through mutation or post-translational modification (Figure 1).27-31
1.3 β-Lactam antibiotics: mode of action
β-Lactam antibiotics are one of the most prescribed antibiotics as a preventive measure against a
vast amount of bacterial infections. Penicillin, the first commercially available antibiotic, as well
as cephalosporin, carbapenem, and monobactam belong to this broad class of β-lactam antibiotics

3

used to treat both Gram-positive and Gram-negative pathogenic bacteria (Figure 2). 32 All β-lactam
antibiotics, including different generations and derivatives of penicillins and cephalosporins, share
a core β-lactam ring in their structure which is responsible for their bactericidal activity.

33

β-

lactam antibiotics exert their function by inhibiting the cell wall synthesis which is lethal to the
bacteria. 34
The cell wall is a crucial component for both Gram-positive and Gram-negative bacteria to
maintain their cellular shape and integrity. 35 The major component of the bacterial cell wall is two
carbohydrate units named N-Acetyl Glucosamine (NAG) and N-Acetyl Muramic acid (NAM) of
which NAM has a terminal peptide in its chemical structure. 36 During cell wall synthesis, cross
linking of an L-Lys of one NAM with the terminal D-Ala-D-Ala occurs with the help of cell wall
transpeptidases known as penicillin-binding proteins (PBPs), which is also accompanied by an
exclusion of a terminal D-Ala residue from one of the peptidoglycan precursors. 37 As a result, the
cell wall becomes rigid due to the covalent bond between peptide and sugar chains, which acts as
a shield for bacterial cell from osmotic forces. However, β-lactam antibiotics harbor a structural
resemblance to the D-Ala-D-Ala substrates, and they perform their inhibitory action by this
mimicry function. 37 These antibiotics interfere with the activity of PBPs by tightly binding to the
enzyme’s active site at the inner surface of the bacterial cell membrane and ultimately disrupt the
cell wall synthesis, which leads to the loss of viability in most of the bacteria (Figure 3).

34, 38

Covalent modification of PBPs by β-lactam antibiotics also results an irreversible acylation of the
active site serine residue. 39 The lack of cell walls in human host cells makes β-lactam antibiotics
excellent drugs with selectivity towards only bacterial cell.

4

1.4 β-Lactamase: classification and mechanism
Throughout the course of evolution, resistance to β-lactam antibiotics is rapidly emerging. Bacteria
utilize several different mechanisms to exhibit resistance against β-lactam antibiotics such as
enzyme degradation of these antibiotics, or modification of their targets through mutation or their
active expulsion from the cell via active transporter efflux pumps. Production of β-lactamase
enzymes is the most prevalent mechanism of resistance in Gram-negative pathogens against βlactam antibiotics.

40

These enzymes catalyze the hydrolysis of the amide bond present in the β-

lactam ring, which renders the antibiotic ineffective. Although they were identified immediately
after the introduction of penicillin, they have existed in nature for millions of years.

41

β-

Lactamases are classified either based on their sequence identity or hydrolytic mechanism. Bush
and Jacoby partitioned β-lactamases into four groups based on their substrate profiling.

42

An

example of this classification includes penicillinases, which refers to β-lactamases that
preferentially hydrolyze penicillins. Extended-spectrum β-lactamases (ESBLs) refer to extendedspectrum cephalosporinases which are responsible for the degradation of 1st, 2nd, and 3rd
generations of cephalosporin antibiotics. 43-44 Carbapenemases are a group β-lactamases that are
capable of hydrolyzing virtually all β-lactam antibiotics including the last resort carbapenems.45
According to the Ambler classification (aka Molecular classification), β-lactamases are divided
into four classes (A, B, C, D) based on their amino acid sequence similarity and catalytic
mechanism (Figure 4). Classes A, C, and D belong to serine β-lactamases and use an active site
serine nucleophile to carry out catalysis, whereas class B are metallo-β-lactamases (MBLs) that
possess either one or two zinc ions in their active sites to mediate β-lactam hydrolysis. 46-48
The most studied class of β-lactamases is class A which encompasses mostly ESBLs and
carbapenemases.

42

Around 600 enzymes belong to this serine β-lactamase class of which CTX-

5

M, KPC, SHV, and TEM group of enzymes are ubiquitous among many pathogenic bacterial
strains.

49

Class A enzymes use a serine nucleophile (Ser70) in the active site to carry out the

acylation and deacylation step of β-lactam hydrolysis. 50 Both Glu166 and Lys73 are hypothesized
to be responsible to assist in the acylation of substrate through Ser70 alkoxide group and
subsequent activation of a hydrolytic water molecule to carry out the deacylation and product
release stage of the β-lactamase catalytic mechanism. 51-52
Class C β-lactamase enzymes were originally identified as chromosomally encoded and
eventually discovered to be plasmid borne.

53

Members of this class of enzyme are commonly

known as AmpC and they are expressed virtually by all Gram-negative bacteria. 54 Their hydrolytic
reaction mechanism is similar to class A β-lactamases where an active site serine (Ser64) acts as a
nucleophile to attack the β-lactam ring. Different active site residues (e.g., Tyr150 and Lys67) are
hypothesized to facilitate the acylation and deacylation step of the catalytic mechanism through
mediating the deprotonation of Ser64 and subsequent activation of water molecule to assist in
breaking the acyl–enzyme bond. 55-56 Many clinically significant β-lactamases belong to this group
including; CMY-1, ACT-1, MIR-1, FOX-1.53
Class D serine β-lactamases represent the most diverse family of β-lactamases due to their
low sequence similarity of about 20% and wide substrate selectively towards penicillins, extendedspectrum cephalosporins, and carbapenems.

57-58

They are mostly recognized as “Oxacillinases”

due to their efficiency in hydrolyzing oxacillin group antibiotics.59 More than 400 class D βlactamases have been identified mostly in Gram-negative pathogens (e.g., Acinetobacter spp.,
Pseudomonas aeruginosa and Enterobacteriaceae)57, but some class D β-lactamases have been
identified in Gram-positive bacteria as well.60 Like other serine β-lactamases, class D enzymes use
an active site serine to carry out their catalytic mechanism. However, for OXA enzymes, the lysine
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residue present in the SXXK motif must be post-translationally modified to become carbamylated
on the ε-amino group. Previous studies hypothesized that this lysine carbamylation is necessary to
promote the acylation process and subsequently activate a water molecule for the further
deacylation mechanism.61-62 Due to their limited substrate specificity towards penicillins and
narrow spectrum cephalosporins, OXA enzymes were of less clinical relevance until the discovery
of carbapenem hydrolyzing class D β-lactamases (CHDL), which can hydrolyze oxyiminocephalosporins and carbapenems. CHDLs are an ominous threat for the clinical setting because of
their ability to hydrolyze carbapenems which are the last therapeutics to treat multi-drug resistant
bacterial infections. 63-64
MBLs were initially discovered 40 years ago but were not considered a serious health
concern until the emergence of IMP-1, VIM-2, and NDM-1 type carbapenemases. 65-66 They can
hydrolyze virtually all classes of β-lactam antibiotics, including the commonly available classical
β-lactamase inhibitors (e.g., clavulanate, tazobactam, sulbactam), but are sensitive to the
monobactam aztreonam.67-68 MBLs are mostly prevalent in Gram-negative pathogens such as
Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli. 69 Presence of structural
diversity among different MBLs as well as their rapid spread across different species through
transferable mobile genetic elements makes them a difficult drug target. 69 MBLs are divided into
three different subclasses, B1, B2, and B3 based on their sequence similarity. 70-72 Subclass B1 and
B3 MBLs are most active when two zinc ions are in the active site where the Zn1 is coordinated
with three histidines, whereas Zn2 is coordinated with a His, Asp and Cys/His.72 Hydrolysis of βlactam antibiotics by subclass B1 MBLs starts immediately after the proper orientation of the βlactam substrate in the active site where the carbonyl group is interacting with Zn1 and the
carboxylate group present in the substrate is interacting with Zn2. The hydroxide ion which attacks
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the β-lactam ring is positioned between Zn1 and Zn2, and is stabilized by both zinc ions. 73-74 For
Class B2 MBLs, the presence of Zn2 is inhibitory for their catalytic function and their substrate
specificity is limited towards carbapenem antibiotics. 75
1.5 Carbapenems and carbapenemases
Among different β-lactam antibiotics, carbapenems have obtained a special emphasis in the field
of antibiotics discovery due to their broad-spectrum inhibitory properties and higher efficacy
towards many different Gram-positive and Gram-negative bacteria. 76 They are considered as the
last resort in therapeutic regimen for individuals infected with MDR pathogens. 77-78 Most of the
commercially carbapenems (e.g., meropenem, imipenem, doripenem, panipenem) possess a
unique chemical structure different from penicillins and cephalosporins due to the substitution of
a carbon instead of sulfur at C1 position and the presence of a double bond between C2 and C3
which can be tautomerized from C2-C3 to N-C2 position.79-81 In addition, the presence of a
hydroxyethyl group attached to C6 instead of the bulkier acylamino side chain present in
penicillins and cephalosporins makes carbapenem antibiotics resistant to hydrolysis by many
ESBLs. 82 This hydroxyethyl group is attached to C6 in a trans-configuration which many serine
β-lactamases are unable to rotate.

83

The hydroxyethyl group also disfavors the positioning of a

catalytic water molecule near the active site to carry out the deacylation step of β-lactamase
catalysis.84-85 This allows the formation of a stable acyl–enzyme complex which many βlactamases are unable to hydrolyze.
However, bacteria evolved several different mechanisms to exhibit resistance against
carbapenems. Gram-positive bacteria modulate their carbapenem resistance mechanism either
through alteration in their PBPs, thereby decreasing their affinity for the antibiotic. 86-87 In the case
of Gram-negative bacteria, carbapenem resistance is commonly achieved through overexpression
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of efflux pumps or production of carbapenem hydrolyzing β-lactamases which is the most studied
mechanism of carbapenem resistance. 88-90 Carbapenemases are ubiquitous among different classes
of β-lactamases, mostly class A, B and D. Class C β-lactamases are not normally considered as
carbapenemases; however, they facilitate carbapenem resistance properties in combination with
other resistance mechanism through overexpression of CMY-10 and PDC type class C βlactamases. 91-92
Many of the class A carbapenemases (e.g., KPC-2, NmcA and SME-1) have been recently
identified and their structure function relationship studies provide us information about some of
the unique characteristics of their active site residues which is responsible for their carbapenemase
activity. 93-95 These enzymes possess some differences in their active site residues versus ESBLs
(e.g., Ser/Thr237, Tyr/Trp105) and the appearance of a disulfide bond between Cys69 and Cys238.
76

These changes make the class A carbapenemase active site more condensed and hydrophobic

in nature which provides accommodation for trans-hydroxyethyl group of carbapenems to
facilitate

their

hydrolysis.96

These

enzymes

are

most

commonly

encountered

in

Enterobacteriaceae and Serratia marcescens.
Class B β-lactamases all have carbapenemase activity in addition to their ability to virtually
hydrolyze most of the penicillin and cephalosporin antibiotics except for their sensitivity to
aztreonam and metal chelators such as ethylenediaminetetraacetic acid (EDTA).72 Class B βlactamases are mostly identified in multidrug resistant Gram-negative pathogens e.g.
Pseudomonas aeruginosa and Enterobacteriaceae spp. and are responsible for many hospital
acquired infections.

69, 97

Their unique substrate binding and catalytic mechanism as well as in

presence of either one or two metal ions as well as flexibility in the loop surrounding the active
site facilitates the accommodation of a wide variety of β-lactam substrate.98-99 Moreover,

9

emergence of new variants of these MBL enzymes (16 variants for NDM and 46 variants for VIM)
due to the evolutionary selective pressure makes them a challenging antibacterial target. 100-101
Class D carbapenemases exhibits a lot of heterogeneity in their active site configuration,
substrate preference and hydrolytic mechanism.61,

102-103

Mutation and expansion of these

enzymes’ activity along with their rapid identification in clinical isolates of Enterobacteriaceae
endangers the public health concern. 61 Most common class D carbapenemases include OXA-23,
OXA-24/40, OXA-48, OXA-58. Class D carbapenemases usually have different carbapenem
substrate specificities based on their active site architectures.104 Both OXA-23 and OXA-24/40
possess a hydrophobic bridge formed by Met223 and Tyr/Phe112, which is hypothesized to
facilitate their carbapenemase activity through providing a small binding cleft to fit the
carbapenem antibiotics, but not enough for the bulky side chain of oxacillin to fit in.105-106
However, OXA-48 is devoid of this hydrophobic bridge and its active site feature is similar to
OXA-10, which is an OXA non-carbapenemase. 107 The orientation of the β5-β6 loop at the top of
the active site as well as the tautomerization state of the pyrroline ring of carbapenem antibiotics
provides a crucial determinant in carbapenem turnover for OXA carbapenemases. 107
1.6 Current inhibitors against β-lactamases
Identification of β-lactamase inhibitors started in the mid-1970s with the discovery of clavulanate
from a natural product that can act as a suicide inhibitor to inactivate the transferrable
penicillinases TEM-1.108 Since then, medicinal chemists designed and synthesized many penicillin
sulfone analogs with increased β-lactamase activity, of which sulbactam and tazobactam were
made commercially available (Fig 5).109-111 These inhibitors possess a β-lactam ring which has
made them susceptible to isolates harboring multiple resistant mechanisms.112 They have limited
specificity towards serine β-lactamases, no inhibitory properties against MBLs and modest affinity
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toward both ESBLs and serine carbapenemases which render them insufficient to restore
penicillin’s activity against bacteria producing multiple β-lactamase.113-114 This prompted the
effort towards designing non-β-lactam-based β-lactamase inhibitors and three decades after the
introduction of clavulanate, a new non-β-lactam inhibitor was invented called avibactam.115-116
This β-lactamase inhibitor contains a diazabicyclooctane (DBO) ring scaffold that works via a
covalent and reversible mechanism of inhibition against a wide range of serine β-lactamases
including serine carbapenemases.116 Avibactam is approved as a therapeutic agent in combination
with ceftazidime and currently available in the market. 115 Some other DBO scaffolds containing
inhibitors (e.g., Relebactam and RG6080) are also being investigated. However, some KPC-2
variants showed resistance to avibactam by exerting a slow hydrolyzing capability. 117 Design of
boronates as transition state analogs targeting the common tetrahedral intermediate is a recent
approach to target both serine β-lactamases and MBLs simultaneously.118 Previously, acyclic
boronates were studied to target the acyl–enzyme intermediate of serine β-lactamases including
serine carbapenemases. RPX7009, now called vaborbactam, is an example of a synthetic cyclic
boronate inhibitor which was approved by the FDA in combination with meropenem in August
2017.

117-118

Design of cyclic boronates as a dual action inhibitor targeting the structurally and

mechanistically diverse serine β-lactamases and MBLs has revolutionized the concept of
developing novel non-β-lactam inhibitors to a large extent. 119
1.7 Structure-based drug design
Immediately after the introduction of first protein structures in the 1950s and 1960s, rapid
understanding of these excellent therapeutic targets was observed due to a massive development
in the field of genomics, proteomic, structural and computation biology. 120-121 Rapid advancement
in the nuclear magnetic resonance (NMR), X-Ray crystallography, and cryo-electron microscopy
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techniques facilitates the drug discovery approach to identify and optimize new drug leads. This
has led to the emergence of a new structure-based drug discovery (SBDD) approach in the late
1990s, which is now a fundamental part of research in many academic and industrial labs. The
idea behind SBDD is to utilize a rational drug design approach, which starts with the identification
of potential drug targets needed to screen for small molecule libraries. In the case of SBDD, steps
of the drug discovery process are followed iteratively from optimization of a drug candidate to
prepare it for clinical trials with the ultimate hopes for it to reach the market (Figure 5). 122-123 The
first step of SBDD is to determine a therapeutic target and potential ligands which show activity
to the drug target. To accomplish this, the targeted gene must go through certain steps e.g., cloning
and expression followed by purification of the encoded protein, and its structure determination.
For SBDD, the key electrostatic and hydrophobic properties of a binding site of the targeted protein
can be used to design and synthesize new small molecule ligands through different computational
algorithms.

21, 124

The second step is to synthesize and optimize hits to improve the affinity,

efficacy, and selectivity through numerous biochemical and biophysical methods to develop
potential therapeutically and pharmacologically relevant drug candidates.125 Iteration of these steps
is necessary for improvement in efficacy and specificity of the selected leads. The third step of
SBDD is to assess the safety and efficacy of these selected leads in humans through several stages
of clinical trial. 124 Successful completion of clinical evaluation of these drug candidates leads to
the fourth stage of SBDD where these drugs are made available in the market for therapeutic
applications.
1.8 Molecular docking
Molecular docking is a powerful computational tool used to predict protein-ligand intermolecular
interactions with high accuracy, which makes it one of the most popular technique in the field of
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SBDD.

126-127

Different scoring functions have been used in molecular docking algorithms to

identify the binding pose of ligands in the active site of a protein. 126 This technique can also be
used to rank ligands based on different scoring functions after the identification of a binding
conformation of any ligand. Different scoring functions have been utilized to calculate the
intermolecular interactions (e.g., electrostatic interactions, hydrogen bonding, Van der Waals
forces, hydrophobic and hydrophilic interactions, and associated entropy) while avoiding errorprone interactions. 128 Due to the improvement in pace and accuracy, molecular docking can now
be utilized to screen a vast number of protein structures to identify potential biding sites for known
ligands and predict potential adverse drug reactions. Increased accessibility of information about
proteins and ligands as well as rapid advancement in the field of docking algorithm facilitates the
opening of a new era in the drug discovery field. 129
1.9 X-ray crystallography
Numerous techniques have been evolved to get detailed analysis about protein-ligand interactions.
Among them, X-ray crystallography provides an accurate and detailed three-dimensional picture
of macromolecules and their interactions with ligands at the atomic level.

130

Automation in

crystallization set up and imaging, improvements in detector and software level for data collection
and processing has made X-ray crystallography an invaluable tool in the field of SBDD. 131 The
overall process of crystallography includes the expression and purification of the protein of interest
in a large scale and then identifying and optimizing a suitable crystallization condition to obtain a
crystal system for producing high-resolution structures. Protein-ligand complex structures can be
obtained by soaking crystals into the solution containing ligand in an appropriate concentration
(~5-10 mM) or co-crystallization of the protein with ligands.

132

Successful determination of

protein-ligand complex structures by X-ray crystallography provide experimental proof of small
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molecule binding and the structural basis of their affinity towards macromolecules, which is the
fundamental concept of SBDD. 133
1.10 Fragment-based drug discovery
Conventional drug discovery process has been mostly focused on high-throughput screening
(HTS), which is based on screening libraries of high molecular weight compounds to identify a
potential lead interacting with the target protein binding site.

134

HTS has some drawbacks e.g.,

failure in determining small molecules as a starting point, time consuming and expensive process.
The search of an alternative drug discovery approach with higher efficiency and cost effectiveness
has led to the emergence of fragment-based drug discovery (FBDD). FBDD is based on screening
low molecular weight compounds (< 250 Da), which bind to distinct regions of the subpocket of
the target protein active site (Figure 6). 135-137 The fundamental of fragment-based drug discovery
is based on a principle named “Rule of three” e.g. molecular weight of the fragments must be <
300 da, it should have three hydrogen bond donors and acceptors, its logP should be <3 and the
number of rotatable bond in its structure has to be < 3. Identification and optimization of these
small molecules as chemical starting points are then chemically linked together, potentially leading
to the development of a lead-like molecule with improved potency and higher affinity than the
individual fragments (Figure 7). 137 As fragments are smaller in size and less complex than leadlike molecules, there is less chance for unfavorable interactions to occur between the protein and
fragments. The capability of fragments to probe a vast amount of chemical space with higher
efficiency along with the lost startup cost to generate a fragment library establishes FBDD as a
lucrative option in the field of developing small molecule drug candidates. 138
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1.11 Development of non-covalent inhibitors against β-lactamases
Most of the serine β-lactamase inhibitors available in the clinical field today are designed to carry
out covalent inhibition.

118, 139

Despite having success in antibiotic drug discovery, covalent

inhibitors still harbor some significant shortcomings. Covalent inhibitors can raise concern about
potential toxicity due to non-specific binding of the drug or their conversion into reactive
metabolites which can interact with cellular DNA or proteins.

139

More exploration is needed in

the field of developing non-covalent inhibitors against β-lactamases. This is because non-covalent
inhibitors possess some beneficial properties e.g., ease of design that can target binding hotspots
shared by multiple classes of carbapenemases 140, lack of reactive moieties, which can minimize
off-target effects

141

, and vast chemical diversity, which could be a potential way to circumvent

resistance mechanisms.

142

Non-covalent inhibitors can also be utilized to mimic the effect of

covalent modification through optimizing their slow dissociation from the target active site. 143
1.12 Conclusions
Antibiotic resistance conferred by β-lactamases is still considered an unmet challenge in the field
of drug discovery due to their rapid emergence and production of carbapenemase-type enzymes,
which can degrade carbapenems, one of the last treatments available for bacterial infections. We
need more exploration into the structural and mechanistic basis of the substrate specificity of
carbapenemases, as well as identifying novel inhibitors through FBDD and SBDD. This
dissertation will address some of the structural insights of serine and metallocarbapenemases
druggability, structural basis of substrate specificity for OXA-48 class D carbapenemase, and
broad-spectrum inhibitor discovery against multiple classes of carbapenemases based on FBDD
and SBDD.
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1.13 Note to Reader #1
Figure 1.1 in this chapter was previously published by Lewis, K. (2013). 7 Platforms for
antibiotic discovery. Nature Reviews Drug Discovery, 12(5), 371-387 and has been reproduced
with permission (See Appendix 1).
Figure 1.2 in this chapter was previously published by Walsh, C. (2000).

38

Molecular

mechanisms that confer antibacterial drug resistance. Nature, 17;406(6797):775-81 and has been
reproduced with permission (See Appendix 1).
Figure 1.5 in this chapter was previously published by Hol, WG. (1994).

123

Structure-

based drug design: progress, results and challenges. Cell Structure; 15;2(7):577-87 and has been
reproduced with permission (See Appendix 1).
Figure 1.6 in this chapter was previously published by Carr, R. (2004). 137 Fragment-based
lead discovery. Nat Rev Drug Discov. 3(8):660-72 and has been reproduced with permission (See
Appendix 1).
Figure 1.7 in this chapter was previously published by Carr, R. (2004). 137 Fragment-based
lead discovery. Nat Rev Drug Discov. 3(8):660-72 and has been reproduced with permission (See
Appendix 1).
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Figure 1.1 Different mechanisms of antibiotic resistance. Bacteria
utilize several different mechanisms to become antibiotic resistance e.g.
inactivation or modification of enzyme, chemical modification or alteration
of target, reduction in drug penetration, increased expression of efflux
pump to pump drug out of the cell, and bypass of pathways. Adapted with
permission from [7]. See Appendix 1.
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Figure 1.2: Inhibition of transpeptidation and transglycosylation steps of
cell-wall biosynthesis by penicillins. a, Interruption of the normal crosslinking
and strength-conferring enzymes by antibiotics that inhibit the enzyme
(penicillins). b, Inhibition of transpeptidase activity by penicillins through
formation of a slowly hydrolysing covalent acyl enzyme intermediate. Adapted
with permission from [38]. See Appendix 1
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Figure 1.3 β-lactam antibiotics. (A) Ampicillin (example of Penicillins), (B)
Cefotaxime (example of Cephalosporins), (C) Imipenem (example of
Carbapenem), (D) Carumonam (Example of Monobactam).
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Figure 1.4 Classification of β-lactamases. Schematic diagram showing Ambler
classification of β-lactamases
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Figure 1.5: Structure based Drug Discovery paradigm. Adapted with
permission from [123]. See Appendix 1
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Figure 1.6: Comparison of fragment-based drug discovery and high throughput
screening in the field of lead discovery and optimization based on the relative
molecular mass and efficacy of the identified hits. Adapted with permission from
[137]. See Appendix 1
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Figure 1.7: Tethering of fragments using linker molecule to improve its potency. a)
Binding of fragment 1 at one of the binding sites of protein. b) Binding of fragment 2 in
another binding site of the same protein. c) tethering of two fragments using a linker
molecule. Adapted with permission from [137]. See Appendix 1

31

Chapter 2: Active Site Druggability of Carbapenemases and Broad-Spectrum Inhibitor
Discovery

2.1 Note to Reader #1
Portions of this chapter have been reproduced from Torelli NJ*, Akhtar A* (Co-first Author),
DeFrees K*, Jaishankar P, Pemberton OA, Zhang X, Johnson C, Renslo AR, Chen Y (2019).
Active-Site Druggability of Carbapenemases and Broad-Spectrum Inhibitor Discovery. ACS
Infect Dis. 5(6):1013-1021with permission of the 2019 American Chemical Society (see Appendix
1).
2.2 Overview
Serine and Metallo-carbapenemases possess serious health concern due to their capability to
hydrolyze nearly all β-lactam antibiotics. However, the molecular basis for their unique broadspectrum substrate profile is poorly understood, particularly for serine carbapenemases such as
KPC-2. In this study, we have compared the ligand binding properties of KPC-2 with the noncarbapenemase CTX-M-14 using substrates and newly identified small molecules, both of which
are Class A β-lactamases with highly similar active sites. Notably, compared to CTX-M-14, KPC2 was more potently inhibited by hydrolyzed β-lactam products (product inhibition), as well as by
a series of novel tetrazole-based inhibitors selected from molecular docking against CTX-M-14.
These data along with complex crystal structures, helps us to conclude that the KPC-2 active site
has an enhanced ability to form favorable interactions with substrates and small molecule ligands
due to its increased hydrophobicity and flexibility. Such properties are even more pronounced in
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metallo-carbapenemases such as NDM-1, which was also inhibited by some of the novel tetrazole
compounds including one displaying comparable low μM affinities against both KPC-2 and NDM1. Our results suggest that carbapenemase activity confers an evolutionary advantage on producers
via broad β-lactam substrate scope, but also a mechanistic Achilles’ heel that can be exploited for
new inhibitor discovery. The complex structures demonstrate for the first time how non-covalent
inhibitors can be engineered to simultaneously target both serine and metallo-carbapenemases.
Despite the relatively modest activity of the current compounds, these studies also demonstrate
that hydrolyzed products and tetrazole-based chemotypes can provide valuable starting points for
broad-spectrum inhibitor discovery against carbapenemases.
2.3 Introduction
The last decade has seen the rise of carbapenemases able to deactivate carbapenems, often regarded
as antibiotics of last resort.1-5 Many of these enzymes also function as extended spectrum βlactamases (ESBLs) and hydrolyze nearly all other β-lactam antibiotics which makes the situation
more alarming. Among them, KPC-26-9 (Class A) and NDM-110-11 (Class B) enzymes cause the
most serious health concerns. Despite the biomedical importance of KPC-2, the molecular basis
of its carbapenemase activity is not well understood, particularly with regard to its ability to bind
to a wide range of β-lactam substrates. The KPC-2 active site is highly similar to other Class A
enzymes such as CTX-M-14, a common ESBL that lacks carbapenemase activity.

12-14

We have

recently determined two complex structures of KPC-2 bound by hydrolyzed β-lactam products,
the first such complexes obtained with a wild type (WT) serine β-lactamase. 13 Previous studies
have suggested that the newly generated carboxylate group in the product may cause unfavorable
steric and electrostatic interactions in the active site, leading to the release of the product. 15 The
KPC-2 product complexes illustrate the differences between KPC-2 and non-carbapenemases such
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as CTX-M-14, including a more open and hydrophobic active site in KPC-2. Such features are
also observed in NDM-1, which harbors a relatively flat substrate binding pocket with a large
number of hydrophobic residues. 16-17
In this study, we investigate how these unique binding site features manifest themselves in
carbapenemases’ interactions with small molecules, especially, how these properties may translate
into their broad substrate profile and the prospects for inhibitor discovery. Although the use of a
β-lactamase inhibitor in conjunction with a β-lactam antibiotic is a well-established strategy to
counter resistance, including the recent success of broad spectrum cyclic boronate compounds 1821

, developing cross-class β-lactamase inhibitors active against both serine and metallo-

carbapenemases remains extremely challenging because of their fundamentally different catalytic
mechanisms and three-dimensional structures. 18, 22-23 Our results, particularly crystal structures of
novel compounds bound noncovalently by KPC-2 and NDM-1, provide valuable insights for drug
discovery efforts against these clinically important enzymes.
2.4 Results and Discussion
2.4.1 Difference between Carbapenemase and Non-Carbapenemase in product inhibition
Recent determination of two KPC-2 product complex crystal structures, together with previous
NDM-1 product complexes

13, 24-25

, suggest that hydrolyzed β-lactam products can potentially

serve as inhibitors of carbapenemases. In comparison, previous attempts to obtain product
complexes with other WT serine β-lactamase crystals were unsuccessful, partially for reasons
described above. To quantify the difference in interactions with the product, I have tested three
hydrolyzed products, penicillin 1 (penicillin G) and cephalosporin 2 and 3 (cephalothin and
cefotaxime), against the non-carbapenemase CTX-M-14, as well as the carbapenemases KPC-2
and NDM-1 (Table 2.1). Interestingly, all products inhibited KPC-2 much more potently than
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CTX-M-14, despite the highly similar active sites of the two class A β-lactamases. Hydrolyzed
penicillin G did not show any inhibition of CTX-M-14 at the highest concentration tested in our
assays (10 mM), although previous studies showed that hydrolyzed penicillins inhibited other
narrow-spectrum β-lactamases with K i ~ 40 mM.
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In comparison, the hydrolyzed penicillin G

was found to be a high-μM inhibitor of both KPC-2 and NDM-1. Even more impressively,
hydrolyzed cephalothin inhibited KPC-2 and NDM-1 with apparent K i values of 1.96 and 63.5
μM, respectively, while showing only mM affinity for CTX-M-14. Hydrolyzed cefotaxime
showed 500 nM affinity towards KPC-2, 14 µM affinity to NDM-1 and 3.8 mM affinity towards
CTX-M-14. These results demonstrate that the hydrolyzed β-lactams studied interact more
favorably with carbapenemases as compared to otherwise similar non-carbapenemases.
2.4.2 Novel small tetrazole based molecule in the active site of CTX-M-14 and KPC-2
We have previously used a structure-based fragment-screening approach to identify the first nM
non-covalent serine β-lactamase inhibitors using a tetrazole-based scaffold, targeting CTX-M. 2728

We found that the tetrazole ring displays high shape and electrostatic complementarity with an

active site pocket that binds to the substrate C3(4)-carboxylate group in CTX-M. Based on the
conservation of this site in class A β-lactamases, we hypothesized that tetrazole-bearing
compounds may inhibit KPC-2 as well. We virtually screened a series of tetrazole-containing
fragments and lead-sized compounds against CTX-M-14, followed by biochemical evaluation
against CTX-M-14, KPC-2, and NDM-1. The active inhibitors demonstrated enhanced activity
against KPC-2 compared to CTX-M-14, by approximately 5-fold or more (Table 2.2).
To illustrate the structural basis of this difference, we determined the crystal structures of
two compounds in complex with CTX-M-14 and KPC-2, which for the first time demonstrated
that the tetrazole moiety can indeed bind to the C3(4)-carboxylate binding site in other Class A β35

lactamases besides CTX-M enzymes (Fig. 2.1). Compound 3 showed a nearly identical binding
mode for both proteins (Fig. 2.1A - 2.1B). The tetrazole moiety is nestled in a conserved sub pocket
consisting of three polar residues and a Gly. It stacks on top of the relatively flat peptide backbone
surrounding Gly236, and forms three hydrogen bonds with Ser130, Thr235, and Ser/Thr237 in
CTX-M-14/KPC-2. Compound 3 also establishes a hydrogen bond with Asn132 in both proteins.
However, the distal di-chloro-benzene ring engages in more non-polar interactions with Pro104,
Trp105, and Leu167 in KPC-2, in comparison to Asn104 and Tyr105 in CTX-M-14.
Compound 6 adopted slightly different poses in the two class A β-lactamases (Fig. 2.1C2.1D). In CTX-M-14, the tricyclic ring system flips up to interact with Ser237 and the protein
backbone between Ser237 and Gly238 at the end of the β3 strand; in KPC-2, it stacks on top of
Trp105 while forming additional non-polar interactions with Leu167. The more extensive nonpolar interactions of both 3 and 6 in KPC-2 explain the approximately 10x higher binding affinity.
2.4.3 Dual inhibition of Serine and Metallo Carbapenemases by tetrazole molecules
The majority of the newly identified tetrazole compounds did not inhibit NDM-1. This result is
unsurprising, considering that class A and B β-lactamases have drastically different catalytic
mechanisms and three-dimensional structures, and that the compounds were originally selected for
CTX-M-14. However, two compounds, 7 and 8, were active against both KPC-2 and NDM-1,
despite exhibiting little to no activity against CTX-M-14 (Table 2.2). In particular, compound 7
showed K i values of 239 μM for KPC-2 and 56 μM for NDM-1. Unexpectedly, the X-ray complex
crystal structures of 7 clearly revealed the bound ligand to be a regioisomer of the purported
structure (7s) provided by the commercial compound supplier (Fig. 2.2). In KPC-2, the tetrazole
moiety binds in the same pocket as the other complex structures. The carbonyl group is positioned
in the oxyanion hole, formed by the backbone groups of Ser70 and Thr237, and establishes a
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hydrogen bond with Thr237N. The two benzene rings have non-polar contacts with Pro104,
Leu167, and Asn170. In NDM-1, the tetrazole group forms hydrogen bonds with Lys211Nζ and
Asn220N, and also interacts with one of the zinc ions. This is the same subpocket bound by the
substrate C3(4)-carboxylate group in previous NDM-1 product complex structures.16,

24-25

Meanwhile, the amide linker points its oxygen towards the zinc ion, with a distance of 2.5 Å,
suggesting weak interactions. In addition, the distal ring system forms extensive non-polar
interactions with Leu65, Met67, Val73 and Trp93.
We subsequently synthesized compound 7s, the regioisomeric form purported to comprise
the original commercial sample. Compared with 7, analog 7s displayed similar activity for NDM1, but better affinity for KPC-2, resulting in comparable Ki’s for both proteins (44 and 62 µM for
KPC-2 and NDM-1 respectively) and similar ligand efficiency values (0.24 and 0.23 kcal/Heavy
Atom (relative binding free energy/HA)). The crystal structure of 7s with KPC-2 clearly shows
that the amide carbonyl group is positioned outside the oxyanion hole, different from 7 (Figure
2.3). The densities for the two benzene rings are significantly weaker, likely due to potential
alternative conformations. Overall one of the rings is oriented downward to interact with Pro104,
Trp105, and Leu167, whereas the other one points upward to form contacts with the Thr237 side
chain. It appears that the aryl rings of both 7 and 7s can establish many non-polar interactions with
the protein, yet 7s is 5x more potent than 7. We hypothesize this could be due to the displacement
of the structural water in the oxyanion hole by 7, which can be energetically costly due to the three
favorable hydrogen bond interactions the water forms with Ser70 and Thr237. In comparison,
compound 7 establishes only one hydrogen bond with Thr237N through its carbonyl oxygen, while
slightly displacing the carbonyl group of Thr237 due to some unfavorable interactions involving
the bridging five-membered ring (Fig. 2.2).
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Compound 8 also showed comparable activities for both serine and metallo-β-lactamases
(Table 2.2). To further probe the shared binding hot spots of serine and metallo-carbapenemases,
we synthesized a small series of compound 8 analogs, including deconstructed fragments (10, 13,
14) that may serve as a better starting point for future lead optimization (Table 2.3). The results
further demonstrate that the amido-tetrazole scaffold could provide a novel chemotype active
against two structurally different, yet functionally related enzymes. As expected, most of these
compounds did not display better activities than compound 8. Interestingly, compound 13
exhibited higher activity against NDM-1 than 8, even though it lacks one of the aryl side chains.
This observation suggests that the backbone of 8 is sub-optimal in its ability to enable both aryl
groups to interact with protein. In addition, some of the new analogs, particularly 11-13, are less
potent against KPC-2 than NDM-1, underscoring the structural differences between these two
enzymes.
Complex crystal structures were determined for 9, a close analog of 8, with KPC-2 and
NDM-1, showing how this inhibitor is accommodated in the active sites of the two proteins (Figure
2.4). Despite the significant structural difference between these enzymes, side chains in 9 are seen
to interact favorably with residues of both proteins. The amido-tetrazole moiety is anchored
similarly to that of compound 7 in both KPC-2 and NDM-1, although the amide linker is placed
outside the oxyanion hole of KPC-2, resembling compound 7s. The electron densities for the side
chains are relatively weak. There appears to be alternative conformations due to the rotation of the
amide linker, although it is not possible to model them accurately at the current resolutions. Overall
the α-phenyl side chain forms non-polar contacts with Leu167/Asn170 in KPC-2 and Leu65/Trp93
in NDM-1. The aniline side chain establishes less contact with both proteins; it is within van der
waals contact distance with selected atoms of Thr237/Gly239 of KPC-2, and Val73/Asn220 of
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NDM-1. We have also determined several other crystal structures including 8 (Figure 2.5), 10, 12
and 13. The amido-tetrazole groups of these structures adopted similar binding modes to 9, but the
densities for the side chains were also relatively weak for most of these compounds, again
suggesting that the aryl rings cannot form optimal protein contacts when displayed from this
scaffold backbone.
2.4.4 Active site druggability responsible for carbapenemase structure and function
Carbapenemases such as KPC-2 and NDM-1 can hydrolyze nearly all β-lactam compounds. Our
results, particularly those comparing KPC-2 and CTX-M-14, suggest that carbapenemases’ broad
substrate spectrum correlates with their active sites’ enhanced druggability, i.e., ability to interact
favorably with small molecules. The active sites of CTX-M-14 and KPC-2 are similar, with nearly
identical main chain configurations except at the end of the β3 strand (G238/D240 in CTX-M-14
and C238/G239/V240 in KPC-2; note residue 239 is missing in CTX-M-14 due to numbering
conventions) caused by the Cys69-Cys238 disulfide bond in KPC-2. The most significant side
chain differences between the active sites of CTX-M-14 and KPC-2 include N104P, Y105W, and
P167L substitutions. These substitutions increase the hydrophobicity of the active site, while also
making the binding pocket slightly more open, particularly surrounding Pro104 in KPC-2.
Similarly, in NDM-1, there are a large number of hydrophobic residues and the active site is
relatively flat compared with serine β-lactamases. 16-17 In addition, in previous structures, Trp105
has demonstrated considerable side chain flexibility in KPC-2 compared with the equivalent
Tyr105 of CTX-M-14, possibly allowing KPC-2 to adapt to different ligands. 13 This plasticity is
even more evident in NDM-1 with the movement of the Met67-Phe70 loop.

16, 22, 24-25

The

increased hydrophobicity, flexibility, and openness of the active sites enables the carbapenemases
to accommodate a wide range of β-lactams potentially also with enhanced binding affinities.
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Whereas this broad-spectrum substrate profile confers evolutionary advantage in bacterial
resistance, the enhanced active site druggability makes carbapenemases susceptible to novel
inhibitor binding, exposing a key weakness of these enzymes.
Tetrazole-based inhibitors have previously been identified against either serine 28-29 or metalloβ-lactamases 30-31, highlighting the utility of the tetrazole moiety as an anchor for inhibitor binding
in these enzymes. In particular, the placement of the tetrazole moiety in our NDM-1 complex
structures, determined at pH 3.85, is nearly identical to that in a previous complex structure of a
different tetrazole inhibitor and the Bacteroides fragilis metallo-β-lactamase (PDB, 1A8T)
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,

determined at pH 6.6. These observations suggest that the low pH used for our NDM-1 complex
crystals did not affect the binding of the titratable tetrazole group to the protein, most likely because
the pKa of the tetrazole group is perturbed by the interactions with the positively charged Zn ions
and Lys211. Furthermore, to our knowledge, these inhibitors represent the first tetrazole-based
dual-activity compounds active against both serine and metallo-β-lactamases. They are also the
only cross-class inhibitors showing the same mode of action against these enzymes. Previous
inhibitors, including the cyclobutanone analogs of β-lactam antibiotics 32-33, cyclic boronates 21, 34,
alkylboronates
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, and the recently discovered bisphosphonate compounds
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, appear to serve as

non-covalent inhibitors for the metallo enzymes, but deactivate serine β-lactamases mostly
through a covalent mechanism. In addition, despite the success of cyclic boronate inhibitors, crossclass inhibitor development has remained challenging, with most inhibitor discovery efforts
focusing on either serine37-45 or metallo β-lactamases. 46-54
Our biochemical and structural data demonstrate the functional similarities between these two
groups of enzymes and indicate that other tetrazole-based compounds can potentially be developed
as high affinity dual-activity inhibitors. Admittedly, the potencies of the unoptimized compounds
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described herein are relatively modest and are not presented as drug leads per se. Nevertheless,
specific analogs such as 7s exhibit reasonable ligand efficiency values (~0.24 kcal/HA) against
both KPC-2 and NDM-1 and thus represent useful starting points for cross-class inhibitor
discovery. Moreover, the complex crystal structures presented herein demonstrate how an amidotetrazole can occupy the substrate C3(4)-carboxylate binding sub-site in both KPC-2 and NMD-1,
and furthermore reveal additional binding hot spots in the active site. This structural information
should be broadly useful to studies of lead discovery and optimization for these important drug
targets.
The inhibition of KPC-2 and NDM-1 by hydrolyzed β-lactam products, especially hydrolyzed
cephalosporins, suggests the possibility of using these scaffolds in designing carbapenemase
inhibitors.

Our recent structure of CTX-M-14 with a penilloate product, where the newly

generated carboxylate group is eliminated through a decarboxylation process, also demonstrates
the broad potential of these compounds as β-lactamase inhibitors, similar to previous studies on
Bacillus cereus β-lactamase.

55-56

Inhibition by a product fragment of tazobactam was observed

for GES-2 Class A carbapenemase as well, although its distinct structure and binding mode
represents a special case. 57 Interestingly, hydrolyzed piperacillin products have also been shown
to inhibit Pseudomonas aeruginosa PBP3, a member of the penicillin-binding protein (PBP)
family, highlighting the potential value of β-lactam products in novel antibiotic discovery, and the
active site features shared between PBPs and Serine β-lactamases. 58
2.5 Conclusion
In this study we have provided biochemical and structural data which have illustrated unique
ligand binding properties of carbapenemases that can be exploited in novel antibiotic development.
Increased druggability may be characteristic of the active site not only for carbapenemases, but
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also for other enzymes with broad-spectrum substrate profiles. In addition to hydrolyzed β-lactam
products, the amido-tetrazole scaffold described here provides new chemotypes for further
inhibitor discovery targeting both serine and metallo-carbapenemases, in efforts to counter
antibiotic resistance particularly in bacteria co-producing both enzymes.
2.6 Materials and Methods
2.6.1 Construct design
CTX-M-14 and KPC-2 were cloned as previously de-scribed.

13, 27

The NDM-1 gene sequence

(residues 42-270) was cloned into the pET-GST expression vector with an N-terminal 6X His-tag
and thrombin cleavage site. The NDM-1 construct was transformed into NEB 5-alpha competent
E. coli and plated onto an LB agar plate containing 50 µg/mL kanamycin. Single colonies were
grown overnight at 37°C in LB media containing 50 µg/mL kanamycin. A mini-prep kit was used
to isolate plasmid DNA and the nucleo-tide sequence of the NDM-1 construct was verified.
2.6.2 Protein expression and purification
BL21(DE3) competent E . coli cells were transformed and used for protein expression for CTXM-14, KPC-2, and NDM-1. CTX-M-14 and KPC-2 were expressed and purified as previously
described.

13, 27

For NDM-1, BL21(DE3) cells were inoculated into 50 mL LB media containing

50 µg/mL kanamycin and grown overnight at 37°C. For large scale production, 1 L of 2xYT media
containing 50 µg/mL kanamycin was inoculated with 10 mL of the overnight starter culture and
grown at 37°C with shaking until the OD 600 reached 0.6-0.8. To initiate protein expression,
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to 0.5 mM and protein expression was
continued at 20°C for 22 hr. The cell pellet was prepared by centrifugation at 4,000 g for 20 min
at 4°C. The cell pellet was resuspended in 35 mL of buffer A (20 mM HEPES pH 8.0, 500 mM
NaCl, 10% (v/v) glycerol, 20 mM imidazole, 50 µM ZnSO 4 ) with a protease inhibitor cocktail
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tablet (Roche). Cells were lysed through sonication and the cell lysate was centrifuged at 45,000
rpm for 1 hr. The supernatant was filtered and loaded onto a His-trap nickel affinity column (GE
healthcare Life Sciences, USA) previously equilibrated with buffer A. After the sample was
loaded, the column was washed with five column volumes of the same buffer and a linear gradient
of increasing imidazole was used to elute the protein. Fractions containing NDM-1, based on SDSPAGE, were pooled, and exchanged with buffer containing 20 mM Tris-HCl pH 8.0, 150 mM
NaCl, 10% (v/v) glycerol. The 6X His-tag was cleaved at 20ºC using thrombin at a 1:100 ratio
(thrombin:NDM-1). After overnight cleavage, samples were again run through a His-trap nickel
affinity column and the flow through containing untagged NDM-1 was collected. The samples
were then concentrated and prepared for a final gel filtration column run. Before loading the
sample, a superdex 75 16/60 gel filtration column (GE healthcare Life Sciences, USA) was
equilibrated with 20 mM HEPES pH 8.0, 100 mM NaCl, 100 µM ZnSO 4 . The concentration of
the protein was measured through absorbance at 280 nm using an extinction coefficient of 27,960
M-1 cm-1. SDS-PAGE analysis indicated that the protein was more than 95% pure. Protein fractions
were pooled together and concentrated to 20 mg/mL. Protein samples were aliquoted, flash frozen
with liquid nitrogen, and stored at -80°C.
2.6.3 Virtual Screening
A database of commercially available tetrazole-containing compounds was downloaded from
ZINC59 and docked to the active site of an in-house structure of CTX-M-14 using DOCK 3.6 and
procedures described previously.28, 60 The 1000 top ranking compounds were manually examined.
Those showing the best complementarity with the protein and chemical diversity were selected
and purchased.
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2.6.4 Hydrolyzed products
Hydrolyzed penicillin G (1) was purchased from Sigma. Hydrolyzed cephalothin (2) was prepared
as follows. Commercially available cephalothin (37.1 mg, 0.094 mmol, 1.0 eq) was dissolved in
water (47 µL) in a 1.5 mL epi tube, followed by dropwise addition of an aqueous 1M sodium
hydroxide solution (94 µL, 0.094 mmol, 1.0 eq). The tube was lightly vortexed for two minutes,
allowed to sit for 15 minutes, then cooled to 0 °C with an ice bucket. A cooled 1M solution of HCl
(188 µL, 0.188, 2.0 eq) was then added dropwise, and the resulting precipitate was filtered and
washed with 2 mL 1M HCl and 2 mL cold water. The resulting tan powder was dried under hivac,
affording 2 (8.5 mg, 26%) as a light tan solid.
2.6.5 Novel inhibitors
Commercially available compounds were purchased and tested without further purification.
2.6.6 Synthetic Procedures
General Procedures: Reactions were magnetically stirred unless otherwise indicated. Air and/or
moisture sensitive reactions were carried out under an argon atmosphere in oven-dried glassware
using anhydrous solvents from commercial suppliers. Air and/or moisture sensitive reagents were
transferred via syringe or cannula and were introduced into reaction vessels through rubber septa.
All anhydrous solvents used were purchased from Sigma-Aldrich and used without further
purification. Solvents to be employed in flash column chromatography and reaction work-up
procedures were purchased from either Sigma-Aldrich or Fisher Scientific. All other reagents were
obtained commercially and used without further purification, unless otherwise stated. Reactions
were monitored using LCMS and thin layer chromatography (TLC) performed on 0.25-mm EMD
pre-coated glass-backed silica gel 60 F-254 plates. Compounds were visualized under UV light or
through staining with permanganate. Reaction product solutions and chromatography fractions
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were concentrated by rotary evaporation at 30 °C at 20 Torr, then Hi-Vac at 0.5 Torr overnight,
unless otherwise indicated.
Instrumentation: NMR spectra were recorded on a Bruker AvanceIII HD 400 MHz
spectrometer (with 5 mm BBFO Z-gradient Smart Probe) calibrated to CH(D)Cl3 as an internal
reference (7.26 and 77.00 ppm for 1H and 13C NMR spectra, respectively). Data for 1H NMR
spectra are reported in terms of chemical shift (δ, ppm), multiplicity, coupling constant (Hz), and
integration. Data for 13C NMR spectra are reported in terms of chemical shift (δ, ppm). The
following abbreviations are used to denote the multiplicities: s = singlet; d = doublet; dd = doublet
of doublets; dt = doublet of triplets; dq = doublet of quartets; ddd = doublet of doublet of doublets;
t = triplet; td = triplet of doublets; tt = triplet of triplets; q = quartet; qd = quartet of doublets; quin
= quintet; sex = sextet; m = multiplet. LCMS and compound purity were determined using a Waters
Micromass ZQ 4000, equipped with a Waters 2795 Separation Module, Waters 2996 Photodiode
Array Detector, and a Waters 2424 ELSD. Separations were carried out with an XBridge BEH
C18, 5μm, 4.6 x 20 mm column, at ambient temperature (unregulated) using a mobile phase of
water-methanol containing a constant 0.1% formic acid. HPLC was performed on a Waters 2535
Separation Module with a Waters 2998 Photodiode Array Detector. Separations were carried out
with an XBridge BEH C18, 5μm, 19 x 50 mm column, at ambient temperature (unregulated) using
a mobile phase of water-methanol containing a constant 0.05% formic acid.
General Procedure A: A vial is charged with the appropriate carboxylic acid (1.0 equiv),
DMF, and N,N′-diisopropylethylamine (1.0 equiv). HATU (1.05 equiv) is then added, and the
reaction mixture is allowed to stir for 10 minutes. 5-aminotetrazole monohydrate (1.1 equiv) and
N,N′-diisopropylethylamine (1.1 equiv) are subsequently added, and the reaction is stirred at room
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temperature for 24 h or until judged complete by LCMS. The crude reaction mixture is directly
purified by reverse phase HPLC (water/MeOH/0.05% formic acid) to afford the desired product.
General Procedure B: An oven-dried flask is charged with the appropriate carboxylic acid
(1.0 equiv), CH2Cl2 (305 equiv), and DMF (20 drops). Oxalyl chloride (1.1 equiv) is subsequently
added dropwise, and the reaction is stirred at room temperature for 3 h. Separately, 5aminotetrazole monohydrate (2.0 equiv) is suspended in CH2Cl2 (305 equiv) and N,N′diisopropylethylamine (3.0 equiv) in an oven-dried flask. The aforementioned oxalyl chloride
solution is then added dropwise to this solution, followed by a 2.0 mL CH2Cl2 rinse of the parent
flask. The reaction suspension is stirred at room temperature for 24 h or until judged complete by
LCMS. The reaction mixture is concentrated under reduced pressure, taken up in DMF, and
purified by reverse phase HPLC (water/MeOH/0.05% formic acid) to afford the desired product.

1,3-Diphenyl-N-(1H-tetrazol-5-yl)-1H-pyrazole-5-carboxamide (7s*). Commercially available
2,5-diphenyl-2H-pyrazole-3-carboxylic acid (50 mg, 0.189 mmol, 1.0 equiv) was reacted with 5aminotetrazole monohydrate in DMF (1.0 mL) according to general procedure A to afford 7s*
(25.0 mg, 40%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.27 (br s, 1H), 7.72 - 7.11
(m, 11H); 13C NMR (100 MHz, DMSO-d6) δ = 160.45, 145.25, 145.17, 139.57, 129.70, 129.47,
129.31, 129.21, 129.17, 126.08, 109.26; LRMS (ESI) calculated for C17H14N7O [M + H]+ m/z
332.11, found 332.08.
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2-Phenyl-2-(phenylthio)-N-(1H-tetrazol-5-yl)acetamide (8*). Commercially available 2-phenyl2-(phenylsulfanyl)acetic acid (100 mg, 0.409 mmol, 1.0 equiv) was reacted with 5-aminotetrazole
monohydrate according to general procedure B to afford 8* (70 mg, 55%) as a white solid. 1H
NMR (400 MHz, DMSO-d6) δ = 8.20 (s, 0.2H), 7.56 (br d, J = 6.8 Hz, 2H), 7.47 - 7.19 (m, 8H),
5.50 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 168.61, 151.34, 136.35, 134.18, 131.19,
129.69, 129.17, 128.86, 128.01, 55.58; LRMS (ESI) calculated for C15H14N5OS [M + H]+ m/z
312.08, found 312.02.

2-Phenyl-2-(phenylamino)-N-(1H-tetrazol-5-yl)acetamide

(9).

Commercially

available

anilino(phenyl)acetic acid (50 mg, 0.220 mmol, 1.0 eq) was reacted with 5-aminotetrazole
monohydrate in DMF (2.5 mL) according to general procedure A to afford 9 (12.6 mg, 20%) as a
white solid. 1H NMR (400 MHz, CD3OD) δ = 7.59 (br s, 2H), 7.49 - 7.28 (m, 3H), 7.13 (br t, J =
7.3 Hz, 2H), 6.82 - 6.63 (m, 3H), 5.22 (br s, 1H); 13C NMR (100 MHz, CD3OD) δ = 171.73,
161.72, 146.78, 137.62, 128.73, 128.56, 128.18, 127.39, 118.00, 113.44, 62.46; LRMS (ESI)
calculated for C15H15N6O [M + H]+ m/z 295.12, found 294.88.
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2-(Phenylamino)-N-(1H-tetrazol-5-yl)acetamide (10). Commercially available phenyl glycine (50
mg, 0.331 mmol, 1.0 equiv) was reacted with 5-aminotetrazole monohydrate in DMF (2.5 mL)
according to general procedure A to afford 10 (7.1 mg, 10%). 1H NMR (400 MHz, CD3OD, drops
DMSO-d6) δ = 8.27 (s, 0.2H), 7.18 (br t, J = 7.5 Hz, 2H), 6.76 - 6.65 (m, 3H), 4.06 (s, 2H); LRMS
(ESI) calculated for C9H11N6O [M + H]+ m/z 219.09, found 218.97.

2-Phenyl-2-(phenylsulfinyl)-N-(1H-tetrazol-5-yl)acetamide (11). (97 mg, 0.374 mmol, 1.0 equiv)
was reacted with 5-aminotetrazole monohydrate in DMF (2.5 mL) according to general procedure
A to afford 11 (8.5 mg, 7%) as a white solid. Note: While the diastereomers are separable by
HPLC, they interconvert on a day’s timescale; the diastereomeric mixture was tested in the
biochemical assay. 1H NMR (400 MHz, CD3OD, drops DMSO-d6)) δ = 8.45 (br s, 1H), 7.79 7.67 (m, 0.5H), 7.66 - 7.05 (m, 9.5H), 5.06 (br s, 0.5H), 4.99 (br s, 0.5H); LRMS (ESI) calculated
for C15H14N5O2S [M + H]+ m/z 328.08, found 327.83.

2-Phenyl-2-(phenylsulfonyl)-N-(1H-tetrazol-5-yl)acetamide (12). (30 mg, 0.109 mmol, 1.0 equiv)
was reacted with 5-aminotetrazole monohydrate according to general procedure B, but with 5 mL
CH2Cl2 (718 equiv) in each vessel. 12 (19.4 mg, 52%) obtained as a white solid. 1H NMR (400
MHz, CD3OD) δ = 8.33 (s, 0.4H), 7.71 - 7.64 (m, 3H), 7.54 - 7.45 (m, 4H), 7.39 (t, J = 7.3 Hz,
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1H), 7.35 - 7.27 (m, 2H); 13C NMR (100 MHz, CD3OD) δ = 162.63, 154.56, 136.78, 134.10,
130.29, 129.44, 129.31, 128.54, 128.39, 128.08, 100.00; LRMS (ESI) calculated for
C15H14N5O3S [M + H]+ m/z 344.07, found 343.86.

2-(Phenylthio)-N-(1H-tetrazol-5-yl) acetamide (13). Commercially available 2-(phenylthio)acetic
acid (100 mg, 0.499 mmol, 1.0 eq) was reacted with 5-aminotetrazole monohydrate in DMF (2.5
mL) according to general procedure A to afford 13 (18.0 mg, 13%). 1H NMR (400 MHz, DMSOd6) δ = 8.16 (s, 0.3H), 7.41 (d, J = 7.5 Hz, 2H), 7.33 (br t, J = 7.5 Hz, 2H), 7.21 (t, J = 7.3 Hz, 1H),
3.95 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ = 167.69, 163.61, 135.92, 129.53, 128.69,
126.65, 36.82; LRMS (ESI) calculated for C9H10N5OS [M + H]+ m/z 236.05, found 235.82.

2-(Phenylsulfonyl)-N-(1H-tetrazol-5-yl)

acetamide

(14).

Commercially

available

2-

(phenylsulfonyl) acetic acid (40 mg, 0.200 mmol, 1.0 equiv) was reacted with 5-aminotetrazole
monohydrate according to general procedure B, but with 5 mL CH2Cl2 (390 equiv) in each vessel.
14 (12.2 mg, 23%) obtained as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.15 (s, 0.5H),
7.92 (d, J = 7.5 Hz, 2H), 7.76 (t, J = 7.3 Hz, 1H), 7.66 (t, J = 7.7 Hz, 2H), 4.58 (s, 2H); 13C NMR
(100 MHz, DMSO-d6) δ = 163.59, 160.11, 139.71, 134.57, 129.75, 128.53, 61.37; LRMS (ESI)
calculated for C9H10N5O3S [M + H]+ m/z 268.04, found 267.78.
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2.6.7 β-lactamase inhibition assays
The hydrolytic activity of CTX-M-14 and KPC-2 was determined using the β-lactamase substrate
nitrocefin in a reaction buffer containing 100 mM Tris pH 7.0 and 0.01% (v/v) Triton X-100.
Nitrocefin hydrolysis was monitored using a Biotek Synergy Mx monochromator-based
multimode microplate reader at 486 nm wavelength. For CTX-M-14 and KPC-2 inhibition assays,
the nitrocefin concentration used was 40 µM and 10 µM, respectively. The K m of nitrocefin for
CTX-M-14 is 22 µM and for KPC-2 is 10 µM. For NDM-1, nitrocefin was used as a substrate in
a reaction buffer consisting of 50 mM HEPES pH 7.2, 50 µM ZnSO 4 , 0.01% (v/v) Triton X-100,
and 1 µg/mL bovine serum albumin (BSA). The K m of nitrocefin for NDM-1 is 3 µM and the
nitrocefin concentration used in the reaction was 10 µM. The tetrazole compounds were purchased
from different companies and used after purification. Compounds were used for IC 50
measurements up to 10 mM based on their solubility in DMSO. The final protein concentration
used in the reaction for CTX-M-14, KPC-2, and NDM-1 was 0.3 nM, 1 nM, and 2 nM,
respectively. The protein was added last to initiate the reaction.
2.6.8 Crystallization and structure determination
CTX-M-14 was crystallized as previously described. 27 Briefly, a 10 mg/mL solution of CTX-M14 was used to grow crystals in 1.0 M potassium phosphate dibasic pH 8.3. CTX-M-14 complex
crystals were prepared via soaking in 1.44 M sodium citrate and 5-10 mM inhibitors for 1-24 hr
based on crystal stability. KPC-2 was crystallized as previously described. Briefly, 10-20 mg/mL
of KPC-2 was used to grow crystals in 2 M (NH 4 ) 2 SO 4 and 5% (v/v) ethanol. KPC-2 complex
crystals were prepared via soaking in 1.44 M sodium citrate and 10 mM inhibitors for 40 min. A
10 mg/mL solution of NDM-1 was used to grow crystals in 0.05 M potassium phosphate
monobasic, 0.01 M calcium chloride, 25% (w/v) PEG8000. Complex NDM-1 crystals were
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prepared via soaking in 0.05 M sodium acetate pH 3.85, 25% (w/v) PEG8000

and 10 mM

inhibitors. Diffraction data was collected at the beamlines 22-ID-D and 23-ID-D of the Advanced
Photon Source (APS), Argonne National Laboratory (ANL) and beamline 8.3.1 at the Advanced
Light Source (ALS), Lawrence Berkeley National Laboratory (LBNL). Data indexing, integration,
and scaling was performed using HKL-2000 61, iMOSFLM 62, and SCALA63 of the CCP4 64 suite.
Phasing was performed using molecular replacement (PDB accession code: 1YLT for CTX-M-14,
3C5A for KPC-2 and 4TZF for NDM-1) with the program phaser65 of the PHENIX suite.66
Structure refinement was performed using phenix.refine

67

of the PHENIX suite and model

building was performed using WinCoot. 68 The eLBOW 69program of the PHENIX suite was used
to generate ligand restraints. The quality of the model was assessed by MolProbity.70 The
composite omit map program71 of the PHENIX suite was used to generate composite simulated
annealing mF o -DF c omit maps. Protein structure figures were generated using PyMOL
(Schrödinger, LLC).
2.7 Note to Reader #2
The compound synthesis described in this chapter were carried out by Kyle DeFrees from Dr.
Renslo lab at the University of California San Francisco, USA.
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Figure 2.1 Complex crystal structure of compounds 3 and 6 with CTX-M-14 and KPC-2.
(A) Compound 3 with CTX-M-14. (B) Compound 3 with KPC-2. (C) Compound 6 with CTXM-14. (D) Compound 6 with KPC-2. The simulated annealing composite F o – F c omit map
(gray) are contoured at 2.5 σ and 2 σ for the CTX-M-14 (1.4 Å resolutions) and KPC-2
structures (1.7-2.2 Å resolutions), respectively. Black dashed lines depict hydrogen bonds
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Figure 2.2 Complex crystal structure of compound 7 with KPC-2 and NDM-1. (A) KPC-2.
(B) NDM-1. The simulated annealing composite F o – F c omit map (gray) contoured at 2.0 σ for
KPC-2 (1.86 Å resolution) and 2.5 σ for NDM-1 (1.15 Å resolution). (B). Black dashed lines
depict hydrogen bonds or coordination with metal ions.
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Figure 2.3 Complex crystal structure of compound 7s with KPC-2. The simulated annealing
composite Fo – Fc omit map (gray) is determined at 1.8 Å and contoured at 1.5 σ for compound
7s with KPC-2. Black dashed lines depict hydrogen bonds.
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Figure 2.4 Complex crystal structure of compound 9 with KPC-2 and NDM-1. (A) KPC-2.
(B) NDM-1. The simulated annealing composite F o – F c omit map (gray) contoured at 2.5 σ (1.42
Å resolution) for KPC-2 and 2σ (1.65 Å resolution) for NDM-1. Black dashed lines depict
hydrogen bonds or coordination with metal ions.
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Figure 2.5 Complex crystal structure of compound 8 with KPC-2 and NDM-1. The simulated
annealing composite Fo –Fc omit map (gray) contoured at 2.0 σ for the 2.0 Å resolution structure
of KPC-2 (A) and the 1.45 Å resolution structure of NDM-1 (B). Black dashed lines depict
hydrogen bonds or coordination with metal ions.
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Table 2.1 Inhibition by hydrolyzed β-lactam products
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Table 2.2 Inhibition by tetrazole-based compounds
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Table 2.3 Inhibition by analogs of compound 8
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Table 2.4 Crystallographic data collection and refinement statistics
Structure

KPC-2
compound 3

KPC-2 compound
6

CTX-M-14
compound 3

CTX-M-14
compound 6

P22 1 2 1

P22 1 2 1

P2 1

P2 1

56.743, 59.244,
76.277
90.00, 90.00,
90.00
27.92 - 1.70
(1.76 - 1.70)
28848 (2799)

56.347 59.768,
77.094
90.00, 90.00,
90.00
47.24 - 2.20
(2.28 - 2.20)
13501 (1257)

45.202, 106.878,
47.781
90.00, 101.89,
90.00
23.38 - 1.40
(1.45 - 1.40)
86581 (8466)

45.34, 107.185,
47.881
90.00, 101.335,
90.00
21.76 - 1.40
(1.45 - 1.40)
86966 (8769)

0.039
51.53 (4.56)
99.75 (98.66)

0.101
12.11 (2.53)
98.20 (93.31)

0.031
48.91 (26.7)
98.83 (96.75)

0.028
49.92 (30.62)
98.76 (99.40)

27.92 - 1.70
0.1802/ 0.2120

47.24 - 2.20
0.2259/0.2780

23.38 - 1.40
0.1478/0.1696

21.76 - 1.40
0.1494/0.1784

2020
76
152

1986
66
20

4060
65
726

4022
120
722

26.75
36.80
36.96

45.59
59.42
40.03

9.15
10.46
21.27

9.93
21.66
22.85

0.007
1.20

0.003
0.65

0.006
1.25

0.006
1.23

Data Collection
Space group
Cell dimensions
a, b, c (Å)
α, β, Υ (°)
Resolution (Å)
No. of unique
reflections
Rmerge (%)
I/σ(I)
Completeness (%)
Refinement
Resolution (Å)
Rwork (%)/ Rfree (%)
No. atoms
Protein
Ligand/Ion
Water
B-factors (Å2)
protein
ligand/ion
water
RMS deviations
Bond lengths (Å)
Bond angles (°)
PDB code
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Table 2.4 Crystallographic data collection and refinement statistics (Continued)
Structure

KPC-2
compound 7

KPC-2 compound
9

NDM-1
compound 7

CTX-M-14
compound 9

P22 1 2 1

P22 1 2 1

P2 1

P2 1

57.112 58.445,
74.563
90.00, 90.00,
90.00
31.43 - 1.86
(1.92 - 1.86)
21576 (2077)

56.05, 59.86,
77.041
90.00, 90.00,
90.00
32.39 - 1.42
(1.471 - 1.42)
49527 (4834)

41.68, 58.87,
42.03
90.00, 98.17,
90.00
33.98 – 1.15
(1.21 – 1.15)
69465 (6837)

41.98, 58.77,
41.98
90.00, 97.48,
90.00
33.97-1.65
(1.774-1.65)
86966 (8769)

0.080
18.06 (2.66)
99.57 (97.79)

0.040
40.54 (2.11)
99.69 (98.45)

0.061
7.4 (2.0)
97.6(96.7)

0.101
9.2 (3.6)
90.96 (81.21)

31.43 - 1.86
0.2277/ 0.2770

32.39 - 1.42
0.1590/0.1883

27.86 - 1.15
0.1669/ 0.1937

33.97-1.65
0.1904/0.2313

2004
31
92

1991
66
110

1731
300

1710
24
130

26.14
28.54
26.97

29.31
49.39
40.58

12.39
12.49
29.38

15.81
23.88
20.80

0.003
0.57

0.006
1.21

0.005
1.18

0.006
1.14

Data Collection
Space group
Cell dimensions
a, b, c (Å)
α, β, Υ (°)
Resolution (Å)
No. of unique
reflections
Rmerge (%)
I/σ(I)
Completeness (%)
Refinement
Resolution (Å)
Rwork (%)/ Rfree (%)
No. atoms
Protein
Ligand/Ion
Water
B-factors (Å2)
protein
ligand/ion
water
RMS deviations
Bond lengths (Å)
Bond angles (°)
PDB code
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Chapter 3: Identification and optimization of heteroaryl phosphonates as non-covalent
inhibitors targeting SBLs and MBLs

3.1 Note to Reader #1
Portions of this chapter have been reproduced from Pemberton OA, Jaishankar P, Akhtar A,
Adams JL, Shaw LN, Renslo AR, Chen Y (2019). Heteroaryl Phosphonates as Noncovalent
Inhibitors of Both Serine- and Metallo carbapenemases. Journal of Medicinal Chemistry, 62(18),
8480-8496 with permission of the 2019 American Chemical Society (see Appendix 1).1
3.2 Overview
Production of carbapenemase enzyme is the most prominent resistance mechanism utilized by
Gram-negative bacteria to withstand most β-lactam antibiotics. Numerous studies have been
performed to design and develop structure based dual inhibitors targeting both serine and metallo
carbapenemases in a cohort function.2-6 In this chapter, I have provided information about a
continuing effort to optimize a heteroaryl phosphonate scaffold as a non-covalent cross class
inhibitor to improve its biochemical and microbiological potency against KPC-2, NDM-1 and
VIM-2 enzymes, as well as pathogenic bacterial strains producing these enzymes. After
identification of a coumarin 4-methyl phosphonate-1 scaffold with high ligand efficiency against
KPC-2 SBL, we performed several iterative substitutions and lead optimization steps, which
ultimately led us to obtain a di-bromo substituent of di-hydroquinolone (DHQ) analog. This dibromo substituent DHQ scaffold exhibited 20 nM and 380 nM affinity towards KPC-2 and VIM2 and 32 µM affinity for NDM-1 when tested through biochemical assay. Minimum inhibitory
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concentration (MIC) analysis showed that this di-bromo phosphonate scaffold has improved the
imipenem efficacy against clinically relevant and laboratory resistant bacterial strains expressing
KPC-2, NDM-1 and VIM-2 type carbapenemases. Complex structures of this scaffold and
analogs for NDM-1 and VIM-2 at low and physiological pH enables us to determine the
influence of pH in their charged state as well as the difference in their binding to the active site
of metallo β-lactamases (MBLs). The design of these phosphonate-based scaffolds and their
inhibitory spectrum encompassing carbapenemases from different multidrug resistant pathogens
provide a potential therapeutic approach in the field of drug discovery targeting antibiotic
resistance.
3.3 Introduction
The most commonly prescribed and effective treatment against serious life threating bacterial
infections are the β-lactam classes of antibiotics. These classes include the penicillins,
cephalosporins, and carbapenems.7 However, over time bacteria have evolved several different
mechanisms to become resistant against these therapeutic regimens. In Gram negative bacteria,
resistance is achieved mostly via production of specific β-lactamase enzymes that degrade the βlactam antibiotics through hydrolysis of the characteristic β-lactam ring.8 Depending on sequence
homology and mechanism of action, β-lactamase enzymes are divided into four classes where
classes A, C and D utilize an active site serine nucleophile to carry out the catalytic hydrolysis
mechanism. Class B enzymes are composed of metallo β-lactamases and are quite different from
the other three classes due to their reliance on either one or two zinc cofactors to mediate the
hydrolytic function.9-10 Production of carbapenemase type β-lactamases is the main mediator
responsible for carbapenem resistance in most of the recently emerged carbapenem-resistant
Enterobacteriaceae (CRE) and Pseudomonas aeruginosa infections causing high rates of
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morbidity and mortality around the world.11-13 Known as last resort antibiotics, the destruction of
carbapenems in therapeutic settings endangers the entire world due to few or no alternative
treatments approach.14 Carbapenemases possess unique active site features to carry out their
substrate specificity and versatile catalytic properties. Some SBL enzymes from Class A, C, and
D and all MBLs harbor carbapenemases activity in addition to penicillinase and ESBLs
activity.15-16 However, MBLs are unable to hydrolyze the monobactam group of β-lactam
antibiotics.17-18
Most of the currently available β-lactamase inhibitors on market are designed to target
SBLs. Examples of these inhibitors include clavulanic acid, tazobactam and sulbactam. These
inhibitors have limited specificity towards class A, C and D β-lactamases but have no activity
towards metallo carbapenemases.17, 19-20 Design of non β-lactam based β-lactamase inhibitors is a
recent approach to combat antibiotic resistance, and avibactam is a prominent example of this
strategy.21 Avibactam exhibits its inhibitory properties to most of the SBLs including
carbapenemases but not against MBLs.22-23 However, resistance to avibactam has been exhibited
in some class A and D serine carbapenemases.24-25 Use of synthetic cyclic boronates to develop
cross-class inhibitors targeting both serine and metallo β-lactamases is a unique example to
address this demanding issue.2, 26
This study provides information about a continuing project describing structure-based
identification and development of a novel phosphonate-based scaffold to investigate its activity
against KPC-2, NDM-1, and VIM-2 carbapenemases. Both synthetic chemistry and X-ray
crystallography have been employed to identify and optimize this scaffold to improve its potency
and as a dual inhibitor of SBL and MBL which lead to obtaining a compound exhibiting low nM
to low µM affinity towards KPC-2, NDM-1 and VIM-2 (Figure 3.1). Microbiological and
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cellular cytotoxic analysis showed that this phosphonate scaffold is effective and selective
towards pathogenic bacterial strains in addition to its good pharmacological properties. All these
data provide information about a potential alternative chemotype for future lead optimization
studies to combat carbapenem resistant Gram-negative pathogens.
3.4 Results and Discussion
3.4.1 Optimized novel phosphonate chemotype in the active site of KPC-2
Molecular docking was performed using DOCK 3.5.5427 to identify novel chemotypes from the
ZINC database that targeted KPC-2 β-lactamase in a noncovalent fashion, which lead to the
identification of several hits including coumarin 4-methyl phosphonate-1. Nitrocefin assays were
performed to biochemically evaluate the efficiency of this inhibitor, which showed a 21 µM
inhibition. Different commercial and synthetic analogs of this phosphonate scaffold have been
assessed to probe the structure activity relationship (SAR). Replacement of the O1 position of
the coumarin ring with a nitrogen atom leads to the formation of a 1,2-dihydroquinolone (DHQ)
analog. Substitution at the C5 and C7 position of the DHQ scaffold with bromine produces
compound 16 (Table 3.1). When tested against KPC-2, compound 16 exhibits a Ki of 20 nM
against KPC-2, which is the highest affinity noncovalent inhibitor against any SBLs to date. To
understand the structural basis of the affinity for the DHQ scaffold towards KPC-2, I determined
the x-ray complex structure with KPC-2 at 1.83 Å resolution (Figure 3.2). The ligand was
unambiguously identified in the composite simulated mF o -DF c omit map contoured at 3 σ. In
this complex structure, the phosphonate group of the compound establishes hydrogen bonds with
Ser70, Thr235, Ser237, and Ser130 and also forms a water-mediated hydrogen bond with the
backbone of Thr216. The carbonyl oxygen atom of the phosphonate inhibitor also forms a watermediated hydrogen bond with Arg220 and His274. The coumarin ring establishes a pi-pi stacking
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interaction with the side chain of Trp105, whereas Pro104 and Leu167 provide a non-polar
surface area for interactions with the bromine substitution at the C5 and C7 position. This SAR
analysis provides a basis for improved activity of this di-bromo substituted DHQ scaffold.
3.4.2 Effect of pH in binding of phosphonate inhibitors in the active site of NDM-1 and
VIM-2 MBLs
After obtaining the structural and biochemical activity of the coumarin phosphonate and its
analogs against KPC-2, these compounds were also tested and found to be active against NDM-1
and VIM-2 MBLs. The biochemical affinity data obtained against MBLs mirrors the findings
obtained for KPC-2. Specifically, compounds 9 and 16 for KPC-2 have also shown higher
potency towards NDM-1 and VIM-2. Phosphonate scaffolds were then subjected to structure
determination with NDM-1 and VIM-2 using a low pH soaking condition (pH 3.8). For both
NDM-1 and VIM-2 complex structures with the coumarin and DHQ analogs at pH 3.8, the
phosphonate group is present between two zinc ions in lieu of the hydroxide ion which is
necessary for the catalytic action of MBLs.10 This provides a hint about the protonated
monoanionic state of the phosphonate group due to low pH, which further enables the
phosphonate group to establish a hydrogen bond with the negatively charged carboxylate group
of Asp124.28 Complex structure for NDM-1 at soaking condition containing physiological pH
was attempted to obtain, but the soaking condition deteriorates the NDM-1 crystals. We
hypothesized that this might occur due to the need for a neutral/protonated D199 at the crystal
packing interface of NDM-1. That is our rationale for designing a construct of NDM-1 with a
mutation changing D199 to N199. Crystallization condition for the NDM-1 WT contains 50mM
potassium phosphate monobasic at pH 3.8, 10 mM calcium chloride and 25% (w/v) PEG-8000.
For NDM-1:D199N crystals to grow, the crystallization condition was kept the same except for
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using 50 mM potassium phosphonate dibasic to change pH closer to the physiological pH (pH
7.5). The soaking condition containing physiological pH was then used to determine the complex
structures and NDM-1: D199N complex with compound 7 and 16 obtained. In case of NDM-1:
D199N complex structures at pH 7.5, the hydroxide ion is retained in between two zinc ions
which was not found in WT NDM-1 complex structures at pH 3.8 (Figure 3.3). The phosphonate
group of the compounds is in close proximity to one of the zinc ions and interacting with it and
the hydroxide ion. As a result, there is a shift in the position of the phosphonate group as well as
the rest of the inhibitor, which is also accompanied by changes in the conformation of active site
residues such as Met67 and Phe70. We hypothesized that the use of physiological pH facilitates
the di-anionic state of the phosphonate group, which might result in the overall change in binding
of the inhibitors as well as the ligand binding residues. Comparing NDM-1 structures obtained
from two different pHs for compound 9 and 16 provided a potential explanation for this concept.
When the NDM-1 WT structure with compound 9 was superimposed with the NDM-1: D199N
complexed with compound 16, a flip of the heteroarene ring was noticed (Figure 3.4). This flip
may occur due to the bromine substitutions at the C5-C7 position which might then favor some
possible interactions with His250 and Phe70.
To get information about how physiological pH influences the binding of phosphonate
compounds in the active site of VIM-2, a soaking condition of pH 7.5 was used for VIM-2 and
VIM-2 complex structure with dibromo substituted DHQ analog (compound 16) was obtained
(Figure 3.5a). Comparing VIM-2 complex structures with compound 16 and compound 9
showed significant differences in positioning of the ligand in the active site (Figure 3.5b). For the
VIM-2 complex structure with compound 9, the carbonyl group forms a hydrogen bond with the
side chain of Arg228. However, in case of compound 16, the carbonyl group is positioned
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outward from Arg228 and no hydrogen bond formation was observed. The aromatic DHQ ring of
compound 16 with the dibromo substitutions makes nonpolar interactions with His263, Arg228,
Trp87, Tyr67, and Phe61. Superimposition of both NDM-1 and VIM-2 with compound 16
highlights some of the structural differences in their active site and the reason behind the higher
affinity of compound 16 for VIM-2 compared to NDM-1. Presence of the Gly232-Asn233 loop
as well as Arg228 closer to the ligand binding site makes the VIM-2 active site narrower and
causes the planar peptide bond between Gly232 and Asn2333 to be stacked on top of the DHQ
ring of compound 16. In addition, there are some favorable hydrophobic interactions between the
DHQ ring and the di-bromo substituents with Phe61 and Tyr67. This might provide an
explanation for the ~100-fold higher affinity of compound 16 for VIM-2 compared to NDM-1.
3.4.3 In vitro assessment of compound 16 using checkerboard assay
After obtaining the biochemical and structural information about the binding and inhibitory
properties for compound 16, we then performed the in vitro microbiological assessment of
compound 16 different clinically relevant pathogenic as well as laboratory strains of bacteria. A
checkerboard assay was performed with varying concentration of imipenem and compound 16
against different clinically relevant pathogenic and laboratory strains of Klebsiella pneumoniae
and Pseudomonas Aeroginosa (Table 3.2). We found there was about 128-fold and 32-fold
reduction in the MIC of imipenem, when compound 16 was used at concentration of about 128
µg/ml and 16 µg/ml as an inhibitor. When comparing the use of avibactam at 16 µg/ml
concentration, a 512-fold reduction of the minimum inhibitory concentration (MIC) of imipenem
was observed. These findings provide information about the dose dependent effect of compound
16 as well as its effectiveness in a therapeutically relevant concentration. To further analyze
compound 16, the molecule was fixed at a concentration of 128 µg/ml and used against a series
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of isogenic carbapenemase-expressing P. aeruginosa strains containing either overexpressed or
deleted efflux pumps MexAB-OprM and MexXY-OprM. For the strains which did not express
efflux pumps, the imipenem MIC was reduced 32, and 16-fold for KPC-2, NDM-1, and VIM-2,
respectively. For the strains overexpressing efflux pumps, the imipenem MIC was reduced by 4and 8-fold for NDM-1 and VIM-2, respectively. Overall, MIC results for compound 16
corroborates the results obtained from biochemical assessment for all KPC-2, NDM-1, and VIM2 enzymes. Although for overexpressing efflux pumps, a reduction in potency of compound 16
was observed by up to 4-fold against NDM-1, the inhibitor retained significant cell-based
activity in these bacterial strains.
3.4.4 Assessment of cytotoxicity for compound 16 using HEK-293 cell line
Tthe cytotoxic effect of the phosphonate compounds was evaluated using compound 16 and
human HEK293T cells (Figure 3.6). We found 88% recovery rate at 100 µg/ml and 70% cell
recovery rate at 200 µg/ml concentrations of compound 16, which indicates that compound 16
exhibits cytotoxicity towards human cell line only when its concentration reached at or above
100 µg/ml. MIC experiments showed that, in absence of imipenem there is no antibacterial effect
for either compound 9 or 16 when used at 128 µg/ml concentration. However, there is a
significant reduction in imipenem MIC up to 32-fold at 16 µg/ml of compound which denotes
the possibility of clinical implications of compound 16 due to its notable cell-based activity at
such low concentration. Although, previous studies have mentioned about poor pharmacological
properties of the phosphonoalkylquinoline compounds.27 Therefore, more exploration is needed
to assess the cytotoxic effect of these phosphonate compounds for future lead optimization.
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3.5 Conclusion
One of the most serious health concerns of the 21st century is the emergence of multidrug
resistant Gram-negative pathogens due to their production of carbapenemase. Discovery of
alternative therapeutic approach is an unmet need to counter these resistance mechanisms. This
study provides information about the discovery and development of a series of heteroaryl
phosphonate scaffolds using biochemical, structural, microbiological, and cellular based effort to
improve their efficacy and selectivity as cross class inhibitors targeting both SBLs and MBLs.
We hope to optimize these scaffolds through SAR studies on the basis of common structural
features responsible for the broad substrate spectrum of carbapenemase enzymes.
3.6 Methods and Materials
3.6.1 Construct Design, Protein expression, and Purification.
KPC-2 protein expression and purification was performed as previously described.29 The
expression and purification of WT NDM-1 and VIM-2 was performed as described.1,

29

To

generate NDM-1 D199N mutant construct, site directed mutagenesis was performed using
NDM-1 as a template and cloned onto a pET-GST vector containing 6x His glutathione-Stransferase tag at the N-terminus and a thrombin cleavage site. The NDM-1: D199N gene
sequence (residues 42-270) was cloned onto this vector with an N-terminal 6X His-tag and
thrombin cleavage site. A mini-prep kit was used to isolate plasmid DNA and the nucleotide
sequence of the NDM-1: D199N construct was verified by gene sequencing. BL21(DE3)
competent E. coli cells were transformed and used for protein expression for NDM-1: D199N. It
was purified using the same procedure used for wild type NDM-1. Untagged NDM-1: D199N
was stored at a concentration of 20 mg/ml using a storage buffer containing with 20 mM HEPES
pH 8.0, 100 mM NaCl, 100 µM ZnSO4. The concentration of the protein was measured through
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absorbance at 280 nm using an extinction coefficient of 27,960 M-1 cm-1. SDS-PAGE analysis
indicated that the protein was greater than 95% pure. Protein samples were aliquoted, flash
frozen with liquid nitrogen, and stored at -80°C.
3.6.2 Compound 16 synthetic procedure
Synthesis of [(5,7-dibromo-2-oxo-1,2-dihydroquinolin-4-yl) methyl] phosphonic acid (16)
O
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Step 1. A mixture of 3,5-dibromolaniline (0.5 g, 2.0 mmol), ethyl acetoacetate (0.5 ml,
4.0 mmol) and potassium tert-butoxide (0.022 g, 0.2 mmol) were stirred at 120 oC for 24 h. The
reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer
was dried over magnesium sulfate, concentrated and purified by flash column chromatography
(35% ethyl acetate /hexanes) to obtain 0.1 g (15%) of N-(3,5-dibromophenyl)-3-oxobutanamide
as a brown oil. 1H NMR (400 MHz, CDCl3) δ 9.40 (s, 1H), 7.74 (s, 2H), 7.43 (s, 1H), 3.62 (s,
2H), 2.55 (s, 3H)
Step 2. To a mixture of N-(3,5-dibromophenyl)-3-oxobutanamide (0.090 g, 0.3 mmol) in
acetic acid (0.2 mL), bromine (0.015 ml, 0.3 mmol) was added slowly. After stirring at room
temperature for 3h, acetone (2 mL) was added to the reaction and the mixture was stirred at room
temperature for 18h. The reaction mixture was diluted with ethyl acetate, washed with water and
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brine. The organic layer was dried over magnesium sulfate, concentrated and purified by flash
column chromatography (25 g, 0-60% EA/hex) to obtain 75 mg of 4-bromo-N-(3,5dibromophenyl)-3-oxobutanamide as a pink solid. Added sulfuric acid (0.100 ml, 1.8 mmol) and
stirred at 45 oC for 18h. Added cold water to the reaction mixture and filtered the precipitate
formed. The precipitate was washed with DCM & dried to obtain 65 mg (61%) of 5,7-dibromo4-(bromomethyl)-1,2-dihydroquinolin-2-one as a beige solid. 1H NMR (400 MHz, d6-DMSO) δ
12.15 (br.s, 1H), 7.75 (s, 1H), 7.56 (s, 1H), 6.92 (s, 1H), 5.19 (s, 2H) 13C NMR (100 MHz, d6DMSO) δ 160.56, 146.96, 143.17, 131.48, 127.39, 123.76, 120.11, 119.14, 115.43, 33.99
Step 3. A mixture of 5,7-dibromo-4-(bromomethyl)-1,2-dihydroquinolin-2-one (0.055 g,
0.14 mmol) and triethyl phosphite (0.24 ml, 1.4 mmol) was stirred in dioxane (3.0 mL) at 100 oC
for 24 h. The reaction mixture was concentrated and purified by flash column chromatography
(0-10% methanol/dichloromethane) to obtain 62 mg (98%) of diethyl [(5,7-dibromo-2-oxo-1,2dihydroquinolin-4-yl)methyl]phosphonate as a beige solid. 1H NMR (400 MHz, CDCl3) δ 12.83
(br s, 1H), 7.57-7.66 (m, 2H), 6.77 (d, J = 4.6 Hz, 1H), 4.08-4.41 (m, 6H), 1.29 (t, J = 7.1 Hz,
6H)13C NMR (100 MHz, CDCl3) δ 162.22, 143.96, 143.86, 141.71, 132.89, 126.12, 124.11,
120.06, 119.74, 117.11, 62.76, 62.60, 34.16, 32.80, 16.43, 16.37. LC-MS: m/z = 453 [M+H] +.
3.6.3 Kinetic analysis through nitrocefin assay
The hydrolysis activity of KPC-2, NDM-1 and VIM-2 was determined by using nitrocefin as a βlactam substrate. For KPC-2, the reaction buffer used contain 100 mM Tris pH-7.0 and
0.01%(v/v) Triton X-100. Nitrocefin hydrolysis caused a color change which was monitored by
Biotek Synergy Mx monochromator-based multimode microplate reader at 480 nM wavelength.
For KPC-2, NDM-1, and VIM-2 inhibition assays, the nitrocefin concentration used in the plate
was 10 µM and 50 µM. The Km of nitrocefin for KPC-2 is about 10 µM. For NDM-1 and VIM77

2, the reaction buffer as well as the protein dilution buffer contained 50mM HEPES pH-7.2, 50
µM ZnSO4, 0.01%(v/v) Triton X-100 and 1µg/ml BSA. The Km of nitrocefin for NDM-1 is 3
µM and VIM-2 is about 45 µM. The phosphonate compounds were used for IC50 measurements
up to 2mM based on their solubility in dimethyl sulfoxide (DMSO). The final concentration used
in the reaction plate for KPC-2, NDM-1 and VIM-2 was 0.3 nM, 2 nM and 0.5 nM. Protein was
added to the reaction buffer last.
3.6.4 Protein crystallization and structure determination
KPC-2 and NDM-1 were crystallized and compound soaking was performed as previously
described1. For the NDM-1 D199N mutant, a 15 mg/mL protein stock was used to grow crystals
in 0.05 M potassium phosphate dibasic (pH 8.0), 0.01 M calcium chloride, 25% (w/v) PEG8000.
Complex NDM-1 D199N mutant crystals were prepared via soaking 10 mM inhibitor
concentration for 1−2 h in 0.05 M sodium acetate, pH 7.5, 20% (w/v) PEG 8000. Crystals were
cryoprotected in the same solution as the soaking conditions but supplemented with 20% (v/v)
glycerol and then ﬂash frozen in liquid nitrogen. Crystals of VIM-2 were grown at 20 °C using
hanging-drop vapor diffusion. Protein concentrations ranging from 10 to 20 mg/ mL in 50 mM
HEPES, pH 7.0, 150 mM NaCl, and 50 μM ZnSO4 were mixed in a 1:1 ratio with reservoir
solution containing 200 mM calcium acetate (pH 7.0), 20% (w/v) PEG 3350, and 1 mM TCEP.
Crystals typically formed in two days. For complex structures obtained at pH-7.5, VIM-2
complex crystals were prepared via soaking in 0.05 M sodium acetate, pH 7.5, 20% (w/v)
PEG8000, and 10 mM inhibitors for about 1 h. The soaked crystals were cryoprotected in a
solution the same as the soaking conditions but with 20% (v/v) glycerol added, and then ﬂashcooled in liquid nitrogen. Data for the KPC-2, NDM-1, and VIM-2 complex structures were
collected using beamlines 19-BM-D, 22-BM-D, and 22-ID-D at the Advanced Photon Source

78

(APS), Argonne National Laboratory (ANL). Diﬀraction data were indexed and integrated with
HKL3000 and scaled with HKL3000 Scale. Phasing was performed using molecular replacement
with the program Phaser 30 of the PHENIX suite 31, with the starting structure KPC-2 (PDB code
5UL8), NDM-8 (PDB code 4TZF), and VIM-2 (PDB code 1KO3). Structure reﬁnement was
performed using phenix.reﬁne

32

of the PHENIX suite and model building in WinCoot.33 The

composite simulated annealing mFo − DFc omit maps were generated using the composite omit
map program34 from the PHENIX suite. The program eLBOW 35 of the PHENIX suite was used
to obtain geometry restraint information. The ﬁnal model qualities were assessed using
MolProbity. 36 All protein structure ﬁgures were generated using PyMOL 2.3.2 (Schrödinger)
3.6.5 Checkerboard assays
Checkerboard assay was performed as described. 1
3.6.6 Cytotoxicity testing
Cytotoxicity testing was performed as described. 1
3.7 Note to Reader #2
The isogenic P. aeruginosa stains expressing various carbapenemases were a kind gift from Dr.
Olga Lomovskaya of QPex Biopharma Inc. The clinical K. pneumoniae strain was kindly
provided by Dr. Yohei Doi (University of Pittsburgh). The Checkerboard assay as well as the
cytotoxicity assessment was performed by Jessie L. Adams from Dr. Lindsey Shaw’s lab at the
CMMB department of the University of South Florida. Compound 16 synthesis procedure was
performed by Priya Jaishankar from Dr. Adam Renslo lab from the UCSF. The initial screening,
molecular docking, and hit identification was performed by Dr. Orville Pemberton.
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Figure 3.1. The dose–response curves of Compound 16 inhibiting the representative MBL
and SBL enzymes. Each experiment was done in triplicate. IC50 values were calculated
separately for each of the triplicate, and then averaged.
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Figure 3.2. Crystal structure reveal binding mode of coumarin phosphonate
analog 16 to KPC-2. The composite simulated annealing mFo −DFc omit maps are
colored in gray and contoured at 3σ. Water molecules are shown as red spheres.
Black dashed lines represent hydrogen bonds.
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Figure 3.3 X-ray crystal structures of NDM-1 bound to phosphonate derivatives at pH 7.5.
The composite simulated annealing mFo − DFc omit maps, determined at 1.30−1.40 Å
resolutions, are colored in gray and contoured at 3σ. Black dashed lines represent hydrogen
bonds. (a) NDM-1 with 16 (PDB code 6NY7). (b) NDM-1 with 7 (PDB code 6D1E).
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Figure 3.4 Superimposition of carbapenemase inhibitor complexes at low and
physiological pH. (c) NDM-1 with 16 (white and green), superimposed with the NDM-1
complex with 9 determined at pH 3.8 (blue, PDB code 6D1G). (d) NDM-1 with 7 (white and
green), superimposed with the same complex determined at pH 3.8 (blue, PDB code 6D1E).
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Figure 3.5 X-ray crystal structures of VIM-2 bound to phosphonate derivative 16 at pH
7.5. The composite simulated annealing mFo − DFc omit map, determined at 2.1 Å resolution,
is colored in gray and contoured at 2σ. Black dashed lines represent hydrogen bonds. (a) VIM2 with 16 (PDB code 6O5T). (b) VIM-2 with 16 (orange and green) superimposed with the
complex of NDM-1 and 16 (blue, PDB code 6NY7).
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Figure 3.6 Cytotoxicity of compound 16 against human HEK293T cell line.
Compound 16 tested at varying concentrations against cells for 48 hours. Percent
recovery calculated based on no drug control containing only solvent. Error bars
represent ± SEM of three replicates.
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Table 3.1. Biochemical Activities of Phosphonate Compounds against KPC-2,
NDM-1, and VIM-2.
Compound

a

a

X

Y

Z

R

R

R

Ki
(KPC-2)
µM

1

O

C=O

C

Me

Me

H

32.9 ± 3.3

0.34

44.3 ± 7.3

2.1 ± 0.1

2

O

C=O

C
OMe

H

H

8.4 ± 0.4

0.39

123.7 ±
3.6

2.1 ± 0.2

OCH 2 O

H

15.3 ± 2.5

0.35

N/A

N/A

1

2

3

L.E.
(KPC2)

Ki
(NDM-1)
µM

Ki
(VIM-2)
µM

3

O

C=O

C

4

O

C=O

C

Me

H

H

23.3 ± 4.6

0.38

N/A

N/A

b

O

C=O

C

H

Me

H

154.4

0.31

N/A

N/A

6

O

C=O

C

Me

H

Me

1.4 ± 0.2

0.45

33.8 ± 3.8

0.82 ± 0.1

7

O

C=O

C
Me

H

Ome

11.9 ± 1.1

0.36

N/A

N/A

5

8

O

C=O

C

F

H

F

9.3 ± 1.8

0.39

No inhib

3.3 ± 0.1

9

O

C=O

C

Me

H

Br

0.246 ± 0.047

0.49

34.2 ± 8.0

1.20 ± 0.16

10

O

C=O

C

Me

H

F

8.5 ± 0.3

0.39

NH

C=O

C

H

H

H

142.3 ± 22.3

0.33

12

NMe

C=O

C

H

H

H

101.5 ± 8.6

0.32

13

NH

C=O

C

Me

H

Me

2.2 ± 0.8

0.43

56.2 ± 4.3

3.4 ± 0.03

11

230.2 ±
3.2
190.2 ±
22.6
81.0 ±
12.8

3.3 ± 0.03
6.4 ± 0.04
7.5 ± 0.02

14

C=C

N

H

H

-

730.4 ± 87.4

0.27

741.3 ±
53.1

22.3 ± 1.3

15

N=C

C

H

H

H

326.1 ± 56.8

0.30

No inhib

30.3 ± 3.2

C

Br

H

Br

0.020 ± 0.007

0.59

31.4 ± 1.9

0.316 ± 0.015

16

NH

C=O
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Table 3.2 In vitro activity (MIC) of imipenem against bacterial strain expressing
KPC-2, NDM-1, and VIM-2 in the presence of Compound 16
Bacterial strain

Characterized
β-lactamase

Imipenem
(µg/mL)

Imipenem+16 (µg/mL)
Imipenem

K. pneumoniae C2

KPC-2

512

P. aeruginosa 4135
P. aeruginosa 4129

KPC-2
NDM-1

P. aeruginosa (eflx+) 4177
P. aeruginosa 4882
P. aeruginosa (eflx+) 4402
P. aeruginosa 4173
P. aeruginosa (eflx+) 4175

16

64
128

16
4
2
8

16
128
128
128

NDM-1
VIM-2

128
32

32
2

128
128

VIM-2
vector
vector

32
2
2

4
-

128
-
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Table 3.3 Crystallographic data collection and refinement statistics.
NDM-1 D199N
compound 7

NDM-1 D199N
compound 16

VIM-2
compound 16

P2 1

P2 1

C2

a, b, c (Å)

41.66, 60.22,
42.50

41.57, 59.77,
42.53

102.39, 79.19,
67.50

α, β, γ (°)

90, 97.98,
90

90, 97.88,
90

90, 130.60,
90

Resolution (Å)

21.85 - 1.30
(1.35 - 1.30)

24.38 -1.40
(1.45 - 1.40)

39.59 - 2.10
(2.172 - 2.10)

Rmerge

0.033 (0.232)

0.039 (0.533)

0.065 (0.314)

27.7 (3.8)

24.1 (2.0)

12.1 (2.1)

99.9 (99.8)

99.5 (98.1)

99.8 (95.5)

3.7(3.0)

3.6(2.8)

3.7 (3.1)

21.85 - 1.30

24.38 -1.40

39.59 - 2.10

50488/4348

40486/3946

23884/2262

0.1535/0.1787

0.1446/0.1756

0.1878/0.2355

Protein

1740

1747

3560

Ligand

21

20

76

Water

296

292

198

Protein

17.62

16.92

28.68

Ligand

18.24

33.32

45.38

Water

31.71

30.77

31.77

Bond lengths (Å)

0.005

0.005

0.006

Bond angles (°)
Ramachandran
plot

0.78

1.00

0.57

Favored (%)

99.12

98.68

97.62

Allowed (%)

0.88

1.32

2.38

Outliers (%)

0.00

0.00

0.00

6O3R

6NY7

6O5T

Data collection
Space group
Cell dimensions

I / σ(I)
Completeness
(%)
Redundancy

Refinement
Resolution (Å)
No.
reflections/free
Rwork/Rfree
No. of atoms

B-factors

R.m.s. deviations

PDB code

*Data were collected from a single crystal for each structure. Values in parentheses are for
highest-resolution shell.
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Chapter 4: Structural basis for substrate specificity and carbapenemase activity of OXA-48
Class D β-lactamase

4.1 Note to Reader #1
Portions of this chapter have been reproduced from Akhtar A, Pemberton OA, Chen Y (2019).
Structural basis for substrate specificity and carbapenemase activity of OXA-48 Class D βlactamase. ACS Infect Dis. with permission of the 2019 American Chemical Society (see
Appendix 1).
4.2 Overview
Carbapenem-hydrolyzing class D β-lactamases (CHDLs) are a diverse family of enzymes that are
rapidly becoming the predominant cause of bacterial resistance against β-lactam antibiotics in
many regions of the world. OXA-48, an atypical member of CHDLs, is one of the most frequently
observed in clinic and exhibits a unique substrate profile. I have applied X-ray crystallography to
OXA-48 complexes with multiple β-lactam antibiotics to elucidate this enzyme’s carbapenemase
activity and its preference of imipenem over meropenem and other substrates such as cefotaxime.
In particular, I have obtained acyl-enzyme complexes of OXA-48 with imipenem, meropenem,
faropenem, cefotaxime, and cefoxitin, and a product complex with imipenem. Importantly, the
product complex captures a key reaction milestone with the newly generated carboxylate group
still in the oxyanion hole and represents the first such complex with a wild type serine β-lactamase.
A potential hydrogen bond is observed between the two carboxylate groups from the product and
the carbamylated Lys73, representing the stage immediately after the breakage of the acyl-enzyme
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bond where the product carboxylate would be neutral. The placement of the product carboxylate
also illustrates the approximate transient location of the deacylation water that has long eluded
structural characterization in class D β-lactamases. Additionally, comparing the product complex
with the acyl-enzyme intermediates provides new insights into the various mechanisms by which
specific side chain groups hinder the access of the deacylation water to the acyl-enzyme linkage,
especially in meropenem. Taken together, these data offer valuable information on the substrate
specificity of OXA-48 and the catalytic mechanism of CHDLs.
4.3 Introduction
Class D β-lactamases (DBLs), commonly referred to as OXA β-lactamases, are a diverse family
of β-lactamases characterized by their low sequence similarity (~20%), structural and functional
variation, and substrate selectivity.1 More than 400 DBLs have been identified, mostly in Gramnegative

pathogens

(e.g.,

Acinetobacter

spp.,

Pseudomonas

aeruginosa,

and

Enterobacteriaceae)1, but some DBLs have also been identified in Gram-positive pathogens.2-3
Like other SBLs, DBLs use an active site serine to carry out their catalytic mechanism. However,
for DBLs, the lysine present in the SxxK motif undergoes post-translational modification to
become carbamylated on the ε-amino group.4 Previous studies have demonstrated that this lysine
carbamylation is essential in the acylation and deacylation steps of DBL catalysis.4-6 During the
deacylation step, the carbamate group is hypothesized to activate a water molecule that attacks and
breaks the acyl-enzyme bond (Figure 4.2). Yet, unlike class A β-lactamases where a wellcoordinated structural water serves this catalytic role7-8, the deacylation water molecule in DBLs
has never been observed in crystal structures. Due to their limited substrate specificity towards
penicillins and narrow-spectrum cephalosporins, DBLs were historically of less clinical relevance
compared with other classes of β-lactamases.9 However, the emergence of carbapenem93

hydrolyzing DBLs (CHDLs) has presented a serious threat for the clinical use of β-lactams due to
their ability to degrade carbapenems10, which are the last-resort therapies used to treat multi-drug
resistant bacterial infections.11-13 DBLs are usually resistant to some commercially available βlactamase inhibitors (e.g., clavulanic acid, sulbactam, and tazobactam), which further complicates
treatment of bacteria producing these enzymes.14 They did, however, show susceptibility towards
the recently developed avibactam and vaborbactam15-16, Many of the clinically relevant CHDLs
are found in Acinetobacter baumannii; these CHDLs include OXA-23, OXA-24/40, OXA-51, and
OXA-58.17-20
The CHDL OXA-48, first discovered from a carbapenem-resistant Klebsiella pneumoniae
isolate, has undergone a different evolutionary pathway compared to other CHDLs14, and has
become the predominant CHDL in clinical isolates from many regions.21-23 OXA-48 is structurally
distinct and shares very low amino acid sequence identity to other CHDLs (e.g., OXA-23 and
OXA-24/40), but possesses similarity to OXA-10, which is an OXA non-carbapenemase.5, 18
OXA-48 has high hydrolytic efficiency towards penicillins but shows poor activity against
extended-spectrum cephalosporins.5 OXA-48 also exhibits substrate specificity towards imipenem
and panipenem over other carbapenems (e.g., meropenem and ertapenem) or penem (faropenem).5,
24

To better understand the structural basis of OXA-48’s substrate specificity towards carbapenems

and its poor cephalosporinase activity, I have determined OXA-48 complex structures with penem
(faropenem), carbapenems (imipenem and meropenem), and cephalosporins (cefotaxime and
cefoxitin) antibiotics. The acyl-enzyme complexes of these β-lactam antibiotics, together with a
product complex with imipenem, provide insights into the carbapenemase activity of CHDLs and
the unique substrate specificity of OXA-48.
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4.4 Results and Discussion
OXA-48 was crystallized at pH 4.6 in the P2 1 space group with four monomers per asymmetric
unit (ASU). The ligand-free crystals were soaked with the various substrates (at slightly higher pH
6.5 to promote ligand binding) for different time intervals (20 min to 1 h). I chose the low pH
condition for crystallization and soaking because it hinders carbamylation of Lys73, thus slowing
down the hydrolysis reaction.5 Consequently, most of the complex structures were determined in
the acyl-enzyme state except for the product complex with imipenem, which was obtained by
increasing the soaking time (2 h). The acyl-enzyme complexes have Lys73 in its decarbamylated
state, whereas the product complex with imipenem contains a carbamylated lysine in its active site.
4.4.1 Acyl-enzyme and product complex structures with imipenem
To gain structural insight into its substrate specificity towards imipenem, OXA-48 was captured
with imipenem as both an acyl-enzyme intermediate and a product complex. Notably, the product
complex represents the first such structure for any wild type DBL. The comparison of the acylenzyme and product complex structures offers important information about the hydrolysis reaction
catalyzed by OXA-48.
The OXA-48: imipenem acyl-enzyme complex structure was solved at a resolution of 2.0
Å with a R work and R free of 17.0% and 21.8%, respectively (Table 4.1). Like all the other acylenzyme complexes herein, a covalent bond between the β-lactam ring carbonyl group and the
catalytic Ser70 hydroxyl group is unambiguously identified in the unbiased Fo-Fc electron density
(Figure 4.3 A). The carbonyl group is placed in the oxyanion hole formed by the backbone amide
groups of Ser70 and Tyr211. Additional hydrogen bonds (HBs) are observed between the C3
carboxylate group and Arg250, as well as between the ring nitrogen and Ser118. The interaction
with Arg250 is common in most SBL-carbapenem complex structures (e.g. Arg244 in TEM-1
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class A β-lactamase), whereas some β-lactamases, such as the OXA-1 subclass of the DBL family,
use a lysine (K212 in OXA-1) to stabilize the carboxylate group.25-26 The pyrroline ring and its
extended C2 side chain establishes non-polar interactions with Tyr211, Leu247 and Ile102. There
is a chloride ion present between Lys73 and Trp157, and it interacts with the Ɛ-amino group of
Lys73 and indole nitrogen of Trp157, as observed in other DBL structures.27-28 Previous studies
have also shown that the carbapenem pyrroline ring can adopt two tautomeric states: ∆1 with the
C2 atom sp3 hybridized, or ∆2 with the C2 atom sp2 hybridized.29-30 The ∆1 tautomer can also
assume two configurations ∆1S and ∆1R, depending on the chirality of the C2 atom. In all four
monomers in the ASU, the electron density clearly suggests that the imipenem pyrroline ring
adopts the ∆1R tautomeric state. In addition, only one conformation of the 6-α-hydroxyethyl
moiety is observed. The hydrocarbon group of this moiety is within van der Waals radii of the
hydrophobic side chains of Val120 and Leu158 (3.5-4.1 Å from Val 120Cγ2 and Leu158Cδ2).
Overall, the acyl-enzyme complex is similar to two previously determined acyl-enzyme complex
structures of OXA-48 with imipenem (Figure 4.3C)31-32, with the majority of changes observed in
the conformation of the flexible C2 side chain and the tautomeric state of the pyrroline ring
(modeled as ∆2 in previous structures).
The OXA-48:imipenem hydrolyzed product structure was solved at 1.75 Å with an R work
and R free of 15.8% and 20.0%, respectively. The unbiased Fo-Fc electron density showed that the
hydroxyl group of Ser70 is not covalently attached to the carbonyl carbon atom of the opened βlactam ring (Figure 4.3B). Rather, a newly generated planar carboxylate group indicates the
presence of a hydrolyzed product of imipenem in the active site. In addition, Lys73 is present in
its carbamylated state, and the carbamate group is within HB distance to the newly generated
product carboxylate (3.0 Å). We hypothesize that at least one of these two usually negatively
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charged groups may be protonated in the current complex due to the low pH of the crystallization
buffer. This HB interaction may also have favored the gradual retention of a carbamylated Lys73
in the active site over a relatively long period of soaking time, despite the low pH that usually
disfavors lysine carbamylation. Interestingly, the product carboxylate group has one oxygen in
the oxyanion hole, corresponding to the ring carbonyl oxygen, while the second oxygen interacting
with the carbamate originates from the deacylation water. Unlike class A β-lactamases, there is no
coordinated structural water in the vicinity of Ser70 in the acyl-enzyme complex structures of
OXA-48 to serve as the catalytic water.33 This second oxygen on the product carboxylate group
provides clues to where the transient catalytic water could be during the deacylation step. In
addition, the OXA-48: imipenem product complex structure is the first time the newly generated
carboxylate group is observed in the oxyanion hole in a product complex with a wild-type (WT)
SBL. It represents the reaction stage immediately after the product is generated in the active site;
when the Lys73 carbamate takes the proton off the deacylation water molecule before subsequently
transferring the proton to Ser70, and the hydroxide forms a covalent bond with the ring carbonyl
carbon atom, leading to a neutral state for the newly generated carboxylate group. Thus, despite
the low pH of the crystallization buffer, the protonation states and HB of the product carboxylate
and Lys73 carbamate in the current structure is likely biologically relevant and corresponds to the
newly formed product in the actual reaction at physiological pH, before its release into the bulk
solvent.
Comparing the new OXA-48 acyl-enzyme and product complexes reveals some important
differences in the ligand configuration, in addition to the product carboxylate group (Figure 4.3D).
First, the pyrroline ring with the C3 carboxylate group of the product is pushed further into the
active site, while maintaining HB interactions with Arg250. This results in the breakage of the HB
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between the ring nitrogen and Ser118, and a new potential HB between the ring nitrogen and Ser70
(3.1 Å). The extended C2 side chain also moves closer to Ile102, and the terminal imino group
forms a HB with Thr104 (2.8 Å). However, the density of this side chain is weak, reflecting its
flexibility. Second, unlike the ∆1R tautomer of the acyl-enzyme complex, the pyrroline ring exists
in the ∆1S tautomeric state in the product complex. The third, and most interesting difference, is
the conformation of the hydroxyethyl group, which undergoes a rotation compared with the acylenzyme. There appears to be an internal HB between the hydroxyl group and the newly generated
carboxylate (2.9 Å), possibly stabilizing this new conformation of the hydroxyethyl group. Lastly,
conformational changes of Ser118, Asp101, and Ile102 are also observed on the protein side
accompanying the various changes in imipenem configuration between the two complexes.
Previous studies have shown that, in the case of OXA-1 (OXA non-carbapenemase), the
carbamylated Lys73 made a HB with the hydroxyethyl group of the carbapenem doripenem, which
hindered the recruitment of a water molecule for the deacylation step.26 But there is no such
interaction present between the carbamate group of Lys73 and imipenem hydroxyethyl group in
either our acyl-enzyme or product complex. Rather, superimposing our two new structures
suggests that the hydroxyethyl conformation in the acyl-enzyme complex could sterically exclude
the deacylation water from approaching the acyl-enzyme bond, with a distance of 1.5 Å between
the methyl group of the acyl-enzyme hydroxyethyl moiety and the oxygen atom of the product
carboxylate group corresponding to the catalytic water. In the product complex, the newly
generated carboxylate group pushed the methyl group of the hydroxyethyl moiety outward from
the hydrophobic pocket formed by Val120 and Leu158, and close to Thr213 (Figure 4.3D). A
similar rotation of the hydroxyethyl group in the acyl-enzyme complex would reduce potential
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steric clashes between this substrate moiety and the deacylation water molecule, clearing the way
for the water to attack the acyl-enzyme linkage.
To gain additional information on OXA-48 carbapenemase activity, the OXA-48
imipenem product complex was superimposed with a previously published OXA-24/40 acylenzyme complex structure with doripenem (Figure 4.4A).34 The carbapenemase activity of OXA24/40 has been hypothesized to rely on the hydrophobic bridge formed by Met223 and Tyr112.
This hydrophobic bridge is absent in OXA non-carbapenemases (e.g., OXA-1, OXA-10 and OXA13), and is speculated to be responsible for the interaction with the side chain of carbapenems as
well as leveraging steric compulsion for the formation of Δ1 S or Δ2 tautomer instead of Δ1 R
tautomer.34-36 However, the importance of this hydrophobic bridge to the carbapenemase activity
has been debated.5, 37-38 Despite its carbapenemase activity, OXA-48 is devoid of this hydrophobic
bridge, and contains Ile102 and Thr213 instead of the corresponding Tyr112 and Met223 in OXA24/40. Previous molecular dynamics studies suggested that rotation of carbapenem’s hydroxyethyl
group is influenced by the OXA-48 active site residues (e.g., Thr213, Leu158, and Val120), which
facilitates the movement of the deacylation water.5 Comparison of the active site residues for our
two new structures supports this hypothesis, as demonstrated by close proximity of these residues
to the hydroxyethyl group in the imipenem acyl-enzyme and product complexes (Figure 4.3D).
To identify the unique features of the OXA-48: imipenem product complex, the structure
was also superimposed with a previously published structure of KPC-2 (class A carbapenemase)
with hydrolyzed faropenem (Figure 4.4B).8 In the case of KPC-2, the newly generated carboxylate
group is located outside the oxyanion hole, whereas Ser70 adopts a different conformation than its
ligand-free form to avoid steric clashes. The difference between the observed product location and
configuration in the KPC-2 and OXA-48 product complexes is likely due to the unique active site
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features of class A and D β-lactamases, coupled with the crystallization conditions, such as pH. In
particular, for KPC-2, the positively charged Lys73 and the polar side chain of Asn132 play an
important role in determining the binding mode of the product through their HBs with the newly
generated product carboxylate group and the amide linker, respectively. Interestingly, the
dihydrothiazole/pyrroline ring of both structures adopts the Δ1S tautomer, whereas the
hydroxyethyl group in the KPC-2:faropenem structure assumes a conformation similar to the
OXA-48 imipenem acyl-enzyme complex, rather than the product complex. The hydroxyethyl
conformation in the KPC-2 structure is likely stabilized by the non-polar interactions with Leu167,
and due to the bulky S1 atom on the ring, as detailed further below. Whereas the OXA-48 complex
captures the product immediately after its generation, the KPC-2 complex represents a snapshot of
the product during its exit from the active site.
4.4.2 Acyl-enzyme complex structures with meropenem and faropenem
To investigate OXA-48’s preference of imipenem over other carbapenems, I have determined the
acyl-enzyme complex structure of OXA-48 with meropenem. I have also obtained a structure of
faropenem bound to OXA-48 as an acyl-enzyme intermediate. Faropenem belongs to the penem
class of antibiotics that possess structural resemblance to both cephalosporins and carbapenems,
and contain a sulfur atom instead of carbon at position 1 of the dihydrothiazole ring (Figure 4.1).39
Both meropenem and faropenem are hydrolyzed by OXA-48 at a much slower rate than
imipenem.5
The OXA-48 meropenem complex structure was determined at 2.0 Å resolution with an
R work and R free of 18.9% and 23.5%, respectively. The OXA-48 faropenem complex structure was
solved at 2.1 Å resolution with an R work and R free of 17.7% and 22.7%, respectively. The binding
poses of both substrates were unambiguously identified in the Fo-Fc electron density maps
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(Figures 4.5A and 4.5B). Superimposition of meropenem, faropenem, and imipenem acyl-enzyme
complexes revealed structural conservation of the binding mode, including the position of the ring
carbonyl group and C3 carboxylate, and the conformation of the hydroxyethyl moiety (Figure
4.5C). The side chains of both meropenem and faropenem establish non-polar interactions with
Ile102, Tyr211, and Leu247, while the terminal group of the meropenem side chain also forms a
HB with Arg250. However, there are differences among the three acyl-enzyme complexes. The
conformation of meropenem is distinguished from those of imipenem and faropenem in that its
pyrroline ring adopts the ∆2 tautomer, in contrast to the ∆1R tautomeric state of imipenem and
faropenem’s pyrroline/dihydrothiazole ring. This is most likely because the ∆1R tautomer of the
pyrroline/dihydrothiazole ring would bring the imipenem and faropenem side chain slightly closer
to Tyr211 and Leu247 and enable them to establish more favorable interactions with one another.
The extensive interactions between the meropenem side chain and Arg250, in addition to Tyr211
and Leu247, may also play a role in meropenem’s preference of the ∆2 tautomer. The electron
density of meropenem is well defined, allowing unambiguous identification of the tautomeric state
of the pyrroline ring. There is some minor ambiguity on the density of the dihydrothiazole ring of
faropenem. Both ∆1R and ∆2 tautomers were attempted during refinement, but the ∆1R tautomeric
state was clearly preferred and allowed the side chain to fit better into the density. Aside from
these differences in the ligand tautomeric states, Ile102 also exhibits minor conformational
variations in the three acyl-enzyme complexes in response to slightly different contacts with the
specific carbapenem/penem side chains.
A key difference among the chemical structures of imipenem, meropenem, and faropenem
is the C1 position of the carbapenem pyrroline ring (unsubstituted in imipenem, methyl in
meropenem), which is a sulfur (S1) in the dihydrothiazole ring of faropenem (Figure 1).
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Superimposition of the meropenem acyl-enzyme complex and the imipenem product complex
suggests that the C1 methyl group of meropenem may impede the rotation of the carbapenem
hydroxyethyl group (with 2.2 Å between the two methyl groups in the superimposed structures),
which is necessary for activation of the deacylation water as shown by our analysis of the
imipenem complexes, and by previous studies (Figure 4.5D).5 This might favor OXA-48 to exhibit
higher catalytic efficiency for imipenem and panipenem compared to other 1-β methyl group
containing carbapenems (e.g., meropenem, doripenem, ertapenem).40 In faropenem, the large
sulfur atom (S1) may have a similar effect in restricting the movement of the hydroxyethyl group,
with a distance of 3.4 Å between the S1 atom of the faropenem acyl-enzyme complex and the
methyl group of the hydroxyethyl moiety in the superimposed imipenem product complex.
Presence of this bulky atom might contribute to the poor hydrolysis rate of OXA-48 towards
faropenem.
Whereas the pyrroline ring assumes Δ2 tautomer in our meropenem acyl-enzyme complex
structure, as well as several other recent OXA-48 acyl-enzyme complexes, there is some
divergence in the planarity of the pyrroline/dihydrothiazole ring among our faropenem and
carbapenem complexes, and among previous complex structures, as summarized by Smith et al.32
For example, the pyrroline ring of doripenem in the OXA-24/40 complex is also present in the Δ2
conformation, but the meropenem pyrroline ring adopts a Δ1 conformation in the acyl-enzyme
complex of OXA-23.24 Such observations appear to challenge the postulation about the necessity
of pyrroline ring tautomerization for the carbapenemase activity of CHDLs.24, 34 This is further
complicated by our observations that the tautomeric states of the pyrroline ring appear to be
different between the acyl-enzyme and product structures. I hypothesize that the
pyrroline/dihydrothiazole ring can most likely adopt both tautomeric states in the acyl-enzyme,
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and its preference is dependent on the interactions between the carbapenem/penem side chain and
the protein.
4.4.3 Acyl-enzyme complex structures of OXA-48 with cefotaxime and cefoxitin
To elucidate the OXA-48 cephalosporinase activity, especially its low efficiency towards
cefotaxime, I determined the acyl-enzyme complex crystal structures of cefotaxime, a relatively
poor substrate for OXA-48, as well as cefoxitin, a β-lactam based β-lactamase inhibitor due to the
presence of 7-α-methoxy group in replacement of hydrogen on the α-face of its β-lactam ring. 33
The presence of the bulk 7-α-methoxy group is hypothesized to be responsible for the displacement
of the deacylation water in class A β-lactamase.33 The complex structure of OXA-48 with
cefotaxime was obtained at 2.0 Å resolution with a final R work and R free of 17.3% and 20.5%,
respectively. The OXA-48:cefoxitin structure was determined to 2.3 Å resolution, and the R work
and R free for this structure are 20.5% and 24.7%, respectively. For both OXA-48 cefotaxime and
cefoxitin structures, the full ligand was identified in the Fo-Fc electron density map, with the
exception of the R2 leaving group, which is removed during the molecular rearrangement that
occurs upon opening of the β-lactam ring, accompanied by the formation of a methylidene group
(Figures 4.6A and 4.6B).41 Some side chain groups, such as the oxyimino moiety of cefotaxime
and the thiophene ring of cefoxitin, also exhibited weak electron density due to their flexibility.
Like other OXA-cephalosporin structures, the dihydrothiazine ring of both cephalosporins is
anchored in the active site pocket consisting of Ser118, Thr209, Arg250, and Trp105.41-42 The C4
carboxylate group of cephalosporin forms electrostatic interactions with the Arg250 side chain,
similar to the C3-carboxylate group in the acyl-enzyme complexes of carbapenems and penem.
The dihydrothiazine ring itself forms stacking interactions with Trp105. The aminothiazole ring
of the cefotaxime side chain establishes stacking interactions with Tyr211, and HBs with the
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Thr213 side chain (2.9 Å). The amide linker also forms a weak HB with the backbone carbonyl
group of Tyr211 (3.2 Å). Meanwhile, the cefotaxime oxyimino side chain is placed in a pocket
formed by Ala69, Leu158, Ser212, Thr213, and Arg214. The same subpocket also accommodates
the thiophene ring of the cefoxitin side chain (Figure 4.6B).
When the OXA-48 cefoxitin structure is compared with the cefotaxime complex structure,
most of the residues interacting with the substrate side chain assumed similar conformations,
except a few residues including Arg214 and Leu158 (Figure 4.6C). In the cefoxitin complex
structure, the Arg214 side chain is pointing outward from the active site to avoid a steric clash
with the thiophene ring. In comparison, the cefotaxime structure has Arg214 positioned close to
the oxyimino side chain. Furthermore, the presence of the additional 7-α-methoxy group on
cefoxitin causes a small rotation in the Leu158 side chain, as well as the movement of Val120, and
consequently Trp105, Asp101, and Ile102 to avoid steric clashes.
Superimposition of the cefotaxime acyl-enzyme complex with the imipenem product
complex structure provides insights into OXA-48’s relatively low activity towards cefotaxime.
Both dihydrothiazine and pyrroline rings were positioned similarly in the active site, while the
cefotaxime side chain is in the same vicinity where the 6-hydroxyethyl group is placed for
imipenem. The placement of this bulky side chain of cefotaxime causes some small conformational
changes for Ile102, Asp101, Trp105, Thr213, Arg214, and Leu158 (Figure 4.6D). More
importantly, the cefotaxime side chain, especially the oxyimino group, partially blocks the access
of potential hydrolytic water molecules to the acyl-enzyme bond, thus reducing the efficiency of
the deacylation reaction. Previous studies have demonstrated that OXA-48 variants, e.g. OXA163, with a S212D substitution and deletion of four residues (214-RIEP-217) in the β5- β6 loop,
have decreased carbapenem hydrolytic properties, but improved efficiency for oxyimino
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cephalosporins.5, 27, 43-44 Similarly, mutations in other CHDLs (e.g., OXA-239, a variant of OXA23; P68A mutant of OXA-48) causing increased flexibility of the β5-β6 loop and nearby regions
also improve the enzymes’ cephalosporinase activity.45 46 Residues 212-214 constitute a major part
of the subpocket that accommodates the cefotaxime oxyimino group. Mutations of these and
nearby residues would open the active site and increase the flexibility of the oxyimino moiety,
allowing water molecules to gain access to the acyl-enzyme bond.
In comparison to the partial hindrance of the hydrolytic water by the cefotaxime side chain,
the 7-α-methoxy group of cefoxitin is placed right next to the imipenem product carboxylate in
the superimposed structures, and completely sterically occludes any water molecule from
approaching the acyl-enzyme linkage. This placement is similar to the previously determined
CTX-M-9:cefoxitin complex structure.33 Furthermore, the 7-α-methoxy group would clash with
the terminal carboxylate of the carbamylated Lys73, and its presence may thus favor an unmodified
lysine. This could further hinder the deacylation process, enabling cefoxitin to be an effective
inhibitor.33, 47
4.5 Conclusion
The fast dissemination of CHDLs, especially OXA-48, in clinical settings has underscored the
need for a deep understanding of these enzymes’ unique β-lactamase activity. Our imipenem
product complex captures the hydrolyzed product immediately after its generation and represents
the first such complex with a WT SBL. Together, with five acyl-enzyme complexes, these
structural findings help us unravel the molecular basis for OXA-48’s carbapenemase activity, as
well as the underlying substrate specificity. Such information could also aid the development of
new inhibitors against CHDLs.
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4.6 Materials and Methods
4.6.1 OXA-48 construct design, expression, and purification
The bla OXA-48 gene (residues 22-263) was synthesized and cloned into the expression vector
pDE441:NH containing an N-terminal His-tag by ATUM. The vector was then transformed into
BL21(DE3) E. coli competent cells for protein expression. For the starter culture, cells were grown
overnight in 50 mL LB broth containing 50 µg/mL kanamycin with shaking at 37°C. For large
scale production, 1 L of 2xYT broth supplemented with 50 µg/mL kanamycin was inoculated with
10 mL of overnight starter culture and incubated at 37°C with shaking until the OD 600 reached
between 0.6-0.8. Then 0.5 mM IPTG was added to initiate protein expression and the culture was
incubated at 20°C for 22 h. After overnight incubation, the cell pellet was prepared by
centrifugation (4000 g/20min, 4°C).
The cell pellet was resuspended in 35 ml buffer A (20 mM HEPES pH-8.0, 300 mM NaCl,
10% (v/v) glycerol, 20 mM imidazole) with a complete EDTA-free protease inhibitor cocktail
tablet (Roche). Cells were lysed by sonication and the disrupted cells were further centrifuged
(45000 rpm/1 h, 4°C). The supernatant was prepared through filtration and loaded onto a HisTrap
HP (GE healthcare Life Sciences, USA) column previously equilibrated with buffer A. After the
sample was loaded, the column was washed with 100 mL buffer A. His-tag OXA-48 was eluted
from the column by running a linear gradient of buffer A to buffer B (20 mM HEPES pH-8.0, 300
mM NaCl, 10% (v/v) glycerol, 500 mM imidazole) and collecting fractions. To assess the purity
of OXA-48, the fractions were analyzed through SDS-PAGE. The fractions containing OXA-48
were then pooled and prepared for the gel filtration chromatography. Before loading the sample, a
HiLoad 16/600 Superdex 75 pg (GE Healthcare) was equilibrated with 20 mM Tris-HCl pH-8.5,
100 mM NaCl. The concentration of the protein was measured through absorbance at 280 nm using
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the predicted extinction coefficient (Δε280 = 65 430cm−1M−1). SDS-PAGE analysis indicated that
the protein was greater than 95% pure. Protein fractions were pooled together and concentrated to
12.5 mg/mL. Protein samples were aliquoted, flash-frozen using liquid nitrogen, and stored at 80°C.
4.6.2 Crystallization of OXA-48
OXA-48 crystals were grown in 0.2 M ammonium acetate, 0.1 M sodium acetate pH-4.6,
30%(w/v) PEG-4000. Hanging drops containing 5 mg/mL protein were mixed with the reservoir
solution in a 3:1 (protein: reservoir) ratio. Micro-seeds prepared using a seed bead (Hampton
Research) were also added to the drops through the streak-seeding method or direct addition of
0.2-0.5 µL micro-seed into the droplets. Crystals formed within a day. To obtain the crystal
complex structures, OXA-48 crystals were soaked into the ligand dissolved solution containing
0.1 M sodium cacodylate (pH 6.5); 40%(v/v) MPD; 5%(w/v) PEG-8000, for about 30 min. OXA48 imipenem product complex structure was obtained by increasing the soaking time up to 2 hr.
After soaking, crystals were collected and cryo-cooled using a cryoprotectant containing 0.1 M
Tris pH-8.5, 30%(w/v) PEG-4000, 20%(v/v) glycerol. The crystals were in the cryoprotectant
buffer for only approximately 3-10 sec, which might not be long enough to change the pH inside
the crystal, particularly in the protein active site. For the product complex, the pH 4.6
crystallization buffer was also used for a separate soaking experiment with imipenem, and the
result was similar to that using the pH 6.5 buffer.
4.6.3 Data analysis and structure determination
Diffraction data for all five crystals was collected using SER-CAT 22-ID and SBC 19-BM at the
Advanced Photon Source (Argonne, IL). Reflection data were indexed, integrated, and scaled
using HKL200048 Phaser49 from the Phenix software suite50 was used for molecular replacement
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with the OXA-48 structure (PDB code: 3HBR)5 used as a starting model. Phenix.refine51 was used
for model refinement and Coot52 was used for model building. Prior to the addition and refinement
of the ligand, the unbiased electron density map (F o - F C ) for the ligand was generated. To acquire
the geometric restraints for the ligand, the program eLBOW in Phenix was used.53 Occupancy of
the ligand was set to 1.0 for the first several cycles of refinement. Then depending on the B factors
for the ligand and surrounding residues, the occupancy was set to less than 1.0 and the refinement
program then optimized the occupancy and B factors for the ligand. For most of the ligands, the
average occupancy was about 0.80-0.97 (Table S2). Evaluation of the model qualities was
performed through MolProbity.54 PyMOL 1.3 (Schrödinger)was used for structural alignment
using pairwise score and for figure preparation.
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Figure 4.1 Structures of cephalosporin (cefotaxime, cefoxitin), penem (faropenem), and
carbapenem (meropenem, imipenem) β-lactam antibiotics.
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Figure 4.2 Catalytic mechanism of carbapenem hydrolysis by Class D β-lactamases.
The carbamylated Lys73 serves as the general base to activate Ser70 and the water in the
acylation and deacylation steps of the reaction respectively. Both ∆1 and ∆2 tautomers of
the pyrroline ring were observed in the acyl-enzyme complexes.
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Figure 4.3 OXA-48 imipenem complexes. The protein and ligand of the new complexes are
shown in white and green, respectively. HBs are shown as black dashed lines. (A) Unbiased
Fo–Fc electron density map (gray) of acylated imipenem (monomer A) contoured to 3σ, with
the chloride ion shown as a yellow sphere. (B) Unbiased Fo–Fc electron density map (gray) of
hydrolyzed imipenem (monomer C) contoured to 3σ. (C) Superimposition of the newly
obtained (white and green) with the previously published (blue, PDB code: 5QB4) OXA-48
acyl–enzyme complex with imipenem (D) Superimposition of the new OXA-48 imipenem acylenzyme complex (white and green) with the new product complex (blue).
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Figure 4.4 Comparison of the OXA-48 product complex with the OXA-24/40 acylenzyme and KPC-2 product complexes. The HBs in the OXA-24/40 and KPC-2 complexes
are shown as black dashed lines. (A) Superimposition of the OXA-48 imipenem product
complex (white and green) with the OXA-24/40 doripenem acyl-enzyme complex (blue, PDB
code: 3PAE). (B) Superimposition of the OXA-48 imipenem product complex (white and
green) with the KPC-2 product complex with faropenem (blue, PDB code: 5UJ4).
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Figure 4.5 OXA-48 meropenem and faropenem acyl-enzyme complexes. The protein and
ligand of the complexes are shown in white and green, respectively. HBs are shown as black
dashed lines. (A) Unbiased Fo–Fc electron density map (gray) of acylated meropenem (monomer
C) contoured to 3σ. (B) Unbiased Fo–Fc electron density map (gray) of acylated faropenem
(monomer A) contoured to 3σ. (C) Superimposition of OXA-48 acyl–enzyme complex with
meropenem (white and green), imipenem (yellow), and faropenem (blue). (D) Superimposition of
OXA-48: meropenem acyl–enzyme complex (white and green) with OXA-48:imipenem product
complex (blue).
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Figure 4.6 OXA-48 cefotaxime and cefoxitin complex. The protein and ligand of the complexes
are shown in white and green, respectively. HBs are shown as black dashed lines. (A) Unbiased Fo–
Fc electron density map (gray) of acylated cefotaxime (monomer C) contoured to 3σ. (B) Unbiased
Fo–Fc electron density map (gray) of acylated cefoxitin (monomer A) contoured to 3σ. (C)
Superimposition of OXA-48:cefotaxime acyl–enzyme complex (green and white) with that of
cefoxitin (blue). (D) Superimposition of OXA-48:cefotaxime acyl–enzyme complex (green and
white) with OXA-48:imipenem product complex (blue).
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Table 4.1 Crystallographic data collection and refinement statistics
OXA-48
Meropenem

OXA-48
Faropenem

OXA-48
Imipenem

OXA-48
Imipenem HP

P2 1

P2 1

P2 1

P2 1

59.79, 106.51,

59.55, 106.67,

58.49,106.66,

58.02, 105.43,

Data collection
Space group
Cell dimensions
a, b, c (Å)

α, β, γ (°)

95.83

96.26

94.66

93.57

90.00, 104.66,

90.00, 104.19,

90.00 107.59

90.00, 107.96

90.00

90.00

30.9 - 2.0

35.1 - 2.1

90.00

90.00

33.0 - 2.0

32.59 - 1.75

Resolution (Å)
(2.1 -2.0)

(2.2 - 2.1)

(2.1 - 2.0)

(1.81 - 1.75)

Rmerge

0.08(0.70)

0.07 (0.37)

0.10(0.57)

0.11(0.83)

Rmeas

0.09 (0.83)

0.09(0.45)

0.16(0.78)

0.13(1.00)

Rpim

0.05(0.45)

0.05(0.25)

0.08(0.41)

0.07(0.55)

0.762

0.920

0.639

0.608

17.4(2.1)

17.5(2.2)

10.6(2.1)

11.1 (2.1)

99.60 (99.70)

98.40 (90.90)

93.20(88.90)

89.50 (84.50)

3.6(3.4)

3.5 (2.7)

3.7(3.6)

6.1(5.8)

30.9 - 2.0

35.1 - 2.1

33.0 - 2.0

32.59 - 1.75

No. reflections/free

77973 (7477)

64787 (5695)

69067 (6376)

95925 (9021)

Reflections(refinement/f
ree)

77881(1999)

64673(1994)

69051(1995)

Rwork/Rfree

0.187/ 0.231

0.177/ 0.227

0.170/ 0.218

8037

8085

8017

CC1/2(outer shell)
I / σ(I)
Completeness (%)
Redundancy

Refinement
Resolution (Å)

95912 (4846)
0.158/0.200

No. of atoms
Protein
Ligand
Water

106
665

78

82

306

893

8033
125
856

B-factors
Protein

34.92

39.43

17.78

16.97

Ligand

46.25

47.35

26.77

31.00

Water

39.71

39.63

Bond lengths (Å)

0.007

0.007

0.003

0.007

Bond angles (°)

0.84

0.84

0.49

0.87

Favored (%)

97.84

97.03

98.14

97.70

Allowed (%)

2.05

2.86

1.86

2.19

26.97

26.83

R.m.s. deviations

Ramachandran plot

Outliers (%)

0.10

0.10

0.00

0.10

PDB code

6PT1

6PSG

6PTU

6PK0

* Values in parentheses are for highest-resolution shell.
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Table 4.1 Crystallographic data collection and refinement statistics (Continued)
OXA-48
Cefotaxime

OXA-48
Cefoxitin

P2 1

P2 1

59.73, 107.01,

60.25, 107.12,

96.19

96.11

90.00, 104.17,

90.00, 104.06,

Data collection
Space group
Cell dimensions
a, b, c (Å)

α, β, γ (°)

90.00

90.00

41.6 - 2.0

26.9 - 2.3

(2.1 - 2.0)

(2.4 - 2.3)

Rmerge

0.07(0.35)

0.06(0.24)

Rmeas

0.08(0.42)

0.07(0.28)

Rpim

0.04(0.22)

0.04(0.15)

Resolution (Å)

CC1/2(Outer shell)
I / σ(I)
Completeness (%)
Redundancy

0.921
21.6 (3.5)

0.948
22.33(4.2)

99.00 (91.00)

97.80 (91.70)

3.6(2.7)

3.7(3.2)

Refinement
Resolution (Å)

41.6 - 2.0

26.9 - 2.3

No. reflections/free

73449 (6532)

51181 (4811)

Reflections(refinement/free)

73283(1995)

51098(2022)

Rwork/Rfree

0.173/ 0.205

0.205/ 0.247

Protein

8072

8053

Ligand

110

102

Water

264

122

Protein

42.97

52.03

Ligand

50.62

56.72

Water

43.60

49.90

Bond lengths (Å)

0.006

0.002

Bond angles (°)

0.78

0.51

Favored (%)

97.34

97.84

Allowed (%)

2.46

2.16

Outliers (%)

0.20

0.00

PDB Code

6PQI

6PT5

No. of atoms

B-factors

R.m.s. deviations

Ramachandran Plot

* Values in parentheses are for highest-resolution shell.
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Chapter 5: Design of fragments and lead like scaffolds to identify novel chemotype for
broad spectrum inhibitor development

5.1 Overview:
Production of carbapenemases are mostly responsible for the recent emergence of CRE and MDR
Pseudomonas Aeruginosa associated infections, which lead to an increase in morbidity and
mortality rates around the world largely due to scarcity of potential therapeutic option. In addition
to carbapenems, these enzymes are also capable of degrading most of the penicillin and
cephalosporin group of antibiotics. Here I report some novel fragments and lead like compounds
targeting multiple clinically relevant carbapenemases (KPC-2, NDM-1 and OXA-48) as well as
the ESBL (CTX-M-14) encompassing classes A, B and D β-lactamases. These compounds were
mostly identified from the ZINC database using a virtual screening approach through molecular
docking with the program DOCK 3.5.54. Compounds were then prioritized based on commercial
availability as well as synthetic feasibility. Subsequent compounds then had binding affinity
assessed through biochemical assays. Most of the scaffolds contain tetrazole, phosphonate and
carboxylate functional groups in the core structure with IC 50 values ranging between 18µM to 2
mM. Crystal structures for NDM-1, KPC-2 and OXA-48 were determined for some phosphonate,
tetrazole and carboxylate containing scaffolds. These selected fragments denote potential novel
chemical scaffold and could be a good starting point for future lead optimization targeting multiple
classes of β-lactamases.
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5.2 Introduction
The administration of β-lactam containing antibiotics remained the most successful treatment
regimen against bacterial infections until the rapid emanation of β-lactamases; most prominent
cause of antibiotic resistance. 1 Serine β-lactamases encompasses Class A, C and D and they mimic
similar catalytic mechanism of PBPs 2-4, whereas metallo β-lactamases are mostly the member of
class B and their hydrolytic mechanism differs mostly due to their reliance on metal zinc ions. 5
Numerous combinatorial approaches e.g. administration of β-lactam antibiotics with β-lactam
based inhibitors have been employed to treat infections caused by serine β-lactamases.6-8 However,
lack of their potency and efficacy against serine and metallo carbapenemases invigorates medicinal
chemists to look for alternative therapeutic choices 9-10 which leads to the design and development
of non β-lactam based β-lactamase inhibitors e.g. avibactam and cyclic boronate inhibitors e.g.
vaborbactam. 11-12 Although these inhibitors and their synthetic analogs are either in clinical trial
or already approved and currently available in the market, their inhibition mechanism relies mostly
on covalent modification of

serine β-lactamase active site which have some potential

pharmacological drawbacks. 13 In addition to that, resistance to avibactam is already observed for
some of Class A and C β-lactamases. 14-15
Development of non-covalent inhibitors targeting multiple classes of carbapenemases is
still an emerging field due to the inherent difficulty in targeting systems with such structural and
mechanistic differences.16-17 Fragment based drug discovery can be a promising solution to said
challenges through identification and optimization of small molecule inhibitors that bind with
lower affinity which further can be tethered through linker molecule to improve potency.18
Fragment based drug discovery is mostly based on screening of low molecular weight (MW <250
Da) compounds aiming sub-pockets of a binding site of the targeted protein.19 Fragments have

122

higher ‘ligand efficiency’ define as-binding energy per heavy atom, than HTS hits that provide a
more absolute depiction of chemical space.

20-22

Most of the fragments are relatively easy to

synthesize and commercially available, which makes them amenable for both structure activity
relationship (SAR) studies using X-ray crystallography or NMR as well as biophysical and
biochemical activity study. 23-26
I have focused on screening a library of 62 fragments through SPR as a preliminary
screening assay method for CTX-M-14. Virtual screening has been performed using a molecular
docking approach to identify several different fragment and lead like hits targeting multiple classes
of β-lactamases. For this, I have used the program DOCK 3.5.54 which can prioritize fragments
based on their complementarity to the ligand binding site as well as binding parameters e.g.
electrostatic interaction, van dar waals forces, hydrogen bonds and hydrophobic interactions.

27

Fragment hits obtained from both SPR screening and molecular docking were further subjected to
secondary biochemical screening for CTX-M-14, KPC-2, NDM-1 and OXA-48 through a specific
β-lactamase assay, which utilizes nitrocefin as a β-lactam substrate. Moreover, crystal structures
were determined for some of the fragments and lead like compounds with higher affinity for KPC2, NDM-1, OXA-48 and CTX-M-14. Using this biochemical and structural information, I aim to
further optimize some of these fragments with reasonable ligand binding affinity to develop broad
spectrum inhibitor against virtually all classes of β-lactamases.
5.3 Results and Discussion
5.3.1. Primary Screening of fragments and lead like compounds against multiple βlactamases using virtual and biophysical screening method
As there are few successful studies concerning fragment screening to develop non-covalent
inhibitors targeting multiple classes of β-lactamases together18,
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28

, I have performed virtual

screening using DOCK 3.5.54 to identify small molecule available from the ZINC database against
CTX-M-14, KPC-2, NDM-1, and OXA-48 which encompasses all classes (A, B, C and D) of βlactamases. For the class A enzymes CTXM-14 and KPC-2, the targeted the binding pocket
consists of Ser70, Ser130, Thr235 and Ser/Thr237; whereas for the class D enzyme OXA-48, the
targeted binding site for docking consists of Ser70, Ser118, Thr209 and Arg250. For NDM-1, the
targeted binding site primarily comprised the residues around Zn2+ coordinated with His189,
Cys208 and Asp124. Top scoring compounds have been visually scrutinized using the program
named PyMol 2.7 and 30 compounds have been chosen based on commercial availability and
purity. Most of the selected compounds were either fragment or lead-like sized compound (M.W.
120-340 Da) and contain electron donating chemical group e.g. carboxylate, tetrazole,
phosphonate and hydroxamate in their structure. These results are unsurprising because previous
studies have described the significance of these electron donating chemotypes present in most of
the clinically relevant inhibitors targeting serine and metallo β-lactamases.29-30 The selected
compounds were then subjected for secondary screening using a biochemical assay.
I have also screened a library of fragments obtained from our collaborator at UCSF against
CTX-M-14, NDM-1 and OXA-48 using an SPR-based screening assay to identify the potential
hits. SPR -based screening method has been vastly utilized tool in fragment-based drug discovery
to screen large library of fragments through determining the affinity and kinetic parameters.31
Fragments were small where their molecular weight ranges from 80-250 Da. and all these
fragments satisfied the rule of three which is the basis of FBDD. 21 All the fragments were analyzed
through primary SPR screening method at a single concentration of 250 uM which results in
identification of 62 fragments binds to CTXM-14, NDM-1 or OXA-48. The selected fragments
were then tested against CTX-M-14 in a concentration dependent serial dilution manner and
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binding affinity as Kd value (equilibrium constant) as well as ligand efficiency (L.E.) has been
determined. Most of the fragments exhibits micromolar affinity for CTX-M-14 and their L.E.
values present within the expected range observed normally for fragment hits.
5.3.2 Determination of binding affinity for the selected compounds using nitorcefin assay
Both molecular docking and SPR assay gave information about the potential hits based on their
standardized procedure but didn’t provide enough evidence to define them as inhibitor per se. To
characterize the inhibitory properties of these fragments and lead like compounds obtained from
both virtual and SPR screening, I have tested them against CTXM-14, NDM-1, KPC-2 and OXA48 using nitrocefin assay. As most of the compounds have been dissolved in DMSO at a high
concentration of 100-200 mM, I had to check the DSMO tolerance of these β-lactamase enzymes
and found that most of them are well tolerated up to 2.5% DMSO in their hydrolyzing capability
to nitrocefin. Among several different hits obtained from molecular docking results (compounds
1-13), compound 1 showed micromolar affinity for KPC-2 (748 µM), NDM-1 (949 µM) and OXA48 (140 µM) (Table 5.1). Besides that, most of the tetrazole based compounds (compounds 1-7)
showed micromolar affinity for NDM-1, of which compound 7 showed 18 µM affinity which is
the highest affinity tetrazole compounds we have identified against NDM-1.
Our lab also studied phosphonate-based compounds to develop cross-class inhibitors
against serine and metallo carbapenemases which led us to obtain lower micromolar, and even a
nanomolar range of compounds targeting KPC-2, NDM-1, and VIM-2 β-lactamases.32 This
invigorates us to look for other potential phosphonate-based scaffolds. From my docking results,
5 phosphonate compounds have been selected and two of them (compound 8 and 9) exhibited µM
Ki values against KPC-2 (500 µM and 99 µM) where compound 9 also showed ~700 µM affinity
against NDM-1. Unfortunately, these phosphonate compounds didn’t show any activity against
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OXA-48. We have also tested some hydroxamate, thiol and carboxylate group containing
compounds but didn’t see potent inhibition against KPC-2, NDM-1 and OXA-48.
Fragments obtained from SPR screening have also gone through this secondary
biochemical screening assay for CTXM-14, KPC-2, NDM-1 and OXA-48. Among 62 different
fragments I have tasted, only 7 (Compounds 13-20) of them showed micromolar affinity against
most of the tested β-lactamases (Table 5.2). Most of these high affinity fragments possess
commonality with a carboxylate group and a heteroaryl ring in their structure and they exhibit
higher affinity against OXA-48 of which compound 16 showed the highest affinity (185 µM) for
OXA-48 among all fragments. In addition to OXA-48 (650 µM), compound 15 also showed
affinity towards KPC-2 (800 µM) and NDM-1 (568 µM). Unfortunately, most of the fragments
didn’t show good affinity against CTX-M-14 and NDM-1.
5.3.3 Reveal binding pose using X-ray crystallography
I have used X-ray crystallography to identify how the µM affinity compounds bind to different
enzymes which also aided to get information about the structural commonality and binding
hotspots present in these enzymes. Among the several different compounds tested, I was able to
capture compound 1 bound to the active site of KPC-2 (1.65 Å), NDM-1 (1.15 Å), OXA-48 (2.3
Å) and CTX-M-14 (1.4 Å) (Figure 5.1). For Both CTX-M-14 and KPC-2, the tetrazole moiety of
compound 1 present in the vicinity of the active site where the C3-carboxylate group of the
substrate normally resides in and forms hydrogen bonds with Thr235, Ser/Thr237 and Ser130. The
hydrophobic portion of compound 1 contains a benzimidazole ring which stacks on top of Trp
/Tyr105 in KPC-2/ CTX-M-14 makes hydrophobic interaction with this residue. For NDM-1, the
tetrazole ring is close to Zn2+ coordinated with His250, Asp124 and Cys208 and makes hydrogen
bond with the backbone amide nitrogen of Asn220 and the Ɛ-amino group of Lys211. The aromatic
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benzimidazole ring is in a hydrophobic area formed Met67, Phe70, Val73 and Trp93 and makes
nonpolar interaction with them. Crystal structure of compound 1 with OXA-48 represents the first
complex structure of any tetrazole based derivatives bound in the active site of OXA-48. In case
of OXA-48, the tetrazole ring compound 1 is anchored in a pocket formed by Lys208, Thr209,
Ser70, Ser 130 and makes hydrogen bonds with Ser118, Thr209, and Arg250. The benzimidazole
ring is located in the vicinity of non-polar residues e.g. Ile102, Trp105 and Val120 and forms pipi stacking interaction with Trp105 and Tyr211.
I have also determined complex structures for NDM-1 with compound 5,6 and 7 (Figure
5.2A, 5.3A, 5.3B) and all these compounds contain tetrazole as a functional group in their
structure. Like compound 1, tetrazole ring for all compounds 5,6, and 7 possess electrostatic
interaction with the Zn2+ as well as some hydrogen bonding interaction with the backbone nitrogen
of Asn220 and the terminal amino group of Lys211.The carbonyl group of the amide side chain
for compound 7 accommodates in a sub pocket of NDM-1 active site formed by His122, Asp124
and Asn220 and establishes a hydrogen bind with the side chain amino group of Asn220. However,
the aromatic indoline ring is in a hydrophobic area constituted by Met67, Phe70, Val73 and Trp93
and forms pi-pi stacking interaction with the side chain of Phe70. Combination of these
hydrophobic contacts as well as several hydrogen bonds and electrostatic interactions can possibly
cause compound 7 to show low micromolar affinity (18 µM) against NDM-1. Compound 5 and 6
are small fragments and besides tetrazole, they don’t have any other hydrophobic functional group
in them to get interact with the hydrophobic residues present in the L3 loop of NDM-1 surrounding
its active site. This could explain the basis of lower affinity of compounds 5 and 6 for NDM-1.
Both biochemical and structural studies provide a potential proof about the reason of higher
affinity of compound 7 against NDM-1, it didn’t show good inhibition against Serine β-lactamases
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(mM range). However, I was able to capture the complex structure of this compound with CTXM-14 (Figure 5.2B) which might provide information about how to optimize compound 7 to
improve its affinity towards β-lactamases while retaining the activity against NDM-1 metallo βlactamase. In case of CTX-M-14, the tetrazole ring of compound 7 makes hydrogen bonds with
Ser130 and Thr235 and the side chain carbonyl group forms a water mediated hydrogen bonding
interaction with Asn132. However, instead of making hydrophobic interactions with Trp105, the
indoline ring of compound 7 is situated in a position formed by Arg222, Ala223 and Arg276 and
formed pi-s stacking interactions with the side chain of both arginine.
I have also obtained complex structure of compound 9 with KPC-2 (Figure 5.4). Surprising,
compound 9 two alternative conformations with approximately similar occupancy which is also
associated with the alternative conformations of Trp105. In case of conformation B for compound
9, the phosphonate group is placed mostly in the oxyanion hole of KPC-2 formed by Ser70 and
the backbone amide of Thr235 and makes hydrogen bonds with Ser130, Thr235 and Thr237.
However, for the conformation of compound 9, the phosphonate group is pushed outward of the
oxyanion hole close to Ser70 and Thr237 and forms hydrogen bonds only with Ser70, Ser130
Thr237 and didn’t interact with Thr235. The aromatic benzodioxin ring for both conformations of
compound 9 is in the same vicinity and stacked on top of one of the conformations of Trp105
through making pi-pi stacking interactions. However, the thiophene ring has positioned in
completely two different orientations for both conformations. For conformation A, the thiophene
ring is anchored in a pocket formed by Trp105, Asn132, Leu167 and Asn170 and makes non-polar
interaction with Trp105 and Leu167. However, the thiophene ring in conformation B is located
close to Thr209 and form nonpolar interactions with alternative conformation of Trp105. I hope to
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utilize these structure activity relationship studies for further hit identification and lead
optimization.
Most of the selected fragments which showed micromolar affinity against multiple classes
of β-lactamases were then subjected for structure activity relationship studies using X-ray
crystallography approach. For this, I have tried to get structures for all 7 fragment compounds
(compound 14-20) with KPC-2, NDM-1 and OXA-48 crystals using different soaking and cocrystallization methods. Unfortunately, for most of the fragments I was not able to determine
structures yet. I have obtained the complex structure of OXA-48 with compound 16 where
fragment is not bound exactly in the active site (Figure 5.5). Compound 16 binds close to the active
site of OXA-48 where its carboxylate group establishes a hydrogen bond with Thr209 and the
aromatic benzofuran ring forms non-polar interaction with the side chain backbone of Lys116.
Previous studies have shown that carboxylate group containing fragments interacts mostly with
Arg250 side chain of OXA-48. However, the complex structure of OXA-48 with compound 16
differs from previous findings. Electron density for compound 16 has been noticed in all four
copies of OXA-48. Although, presence of compound 16 in the crystal packing interface of OXA48 provides a potential clue of crystallographic artifacts. Complex structure for compound 20 with
KPC-2 is also determined which is kind of expected because there are studies about the covalent
binding and inhibitory properties of boronate compounds in the active of serine β-lactamases.
5.4 Conclusion
Since after the introduction of first β-lactamase inhibitors, numerous studies have been focused on
designing covalent inhibitors targeting serine β-lactamases in a covalent fashion. However, much
focus is needed to address this antibiotic resistance culprit in a non-covalent approach to slow
down the arrival of their resistance mechanism as well as to minimize the off target affect to
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improve their pharmacological properties. This study about fragment and lead based screening
targeting multiple classes of β-lactamases helps us to identify some novel noncovalent inhibitors
that showed activity against KPC-2, CTX-M-14, NDM-1 and OXA-48. Although the affinity of
the chosen compounds against these enzymes is still in micromolar to mM range, we hypothesized
that this could due to their non-covalent approach in binding as well as difference in the active site
configuration, substrate binding and catalytic mechanism of these β-lactamases. Most of the
compounds obtained from virtual screening mostly rely on the hydrogen bonding network with
some of the active site residues of KPC-2, CTX-M-14 and OXA-48 and metal ions of NDM-1 as
well as their hydrophobic contact with the residues surrounding the active site. However, increase
hydrophobicity of these selected compounds decline their solubility which might impact their
binding and inhibitory properties in biochemical assay.
The complex structure of compound 1 with KPC-2, NDM-1 and OXA-48 represents the
first such complex for any non-covalent inhibitor targeting multiple classes of carbapenemases to
our knowledge. Although the affinity for this compound is in higher micromolar range which is
not drug like per se; further optimization of compound 1 might improve its potency while
maintaining its broad-spectrum inhibitory properties. This strategy can also be executed for other
fragment and lead like compounds e.g. compounds 4,7, 9, 15 and 16 to design and develop new
chemical scaffolds targeting multiple classes of β-lactamases as well as identifying potential
binding hotspots present among these enzymes. As fragments are smaller in size and their affinity
towards different enzymes is not high enough, it is difficult to get complex structure of these
fragments with particular β-lactamase enzyme. However, utilizing several different soaking and
co-crystallization method may facilitate us in future to determine more complex structure of these
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fragments which might provide us enormous amount of information about their structure activity
relationship and aid us in future broad-spectrum inhibitor discovery.
5.5 Methods and Materials
5.5.1 Protein Expression and Purification
CTX-M-14, KPC-2, NDM-1 have been purified as previously described. 33-35
OXA-48 protein expression and purification has been performed similarly as described before. 36
5.5.2 Molecular docking
To screen fragment and lead like small molecules available on ZINC database, I have utilized a
docking program named DOCK 3.5.54. 27 For this I have used apo structure of CTX-M-14, KPC2, NDM-1 and OXA-48. While performing the docking procedure, the conserved catalytic water/
hydroxide ion was kept remain in the active site of the corresponding protein, while removing
other water molecules. Multiple run of docking procedure was performed with changes in their
side chain partial charges for some the selected active site residues to improve their hydrogen bond
network with the ligand as well as improvement in conformation sampling. Top 500 high ranked
compounds have been visually inspected and compounds which exhibits higher chemical diversity
and complementarity for most of the targeted β-lactamases have been explored for their
commercial availability.
5.5.3 Steady-State kinetic analysis
The hydrolytic activity of KPC-2, CTX-M-14, NDM-1 and OXA-48 β-lactamases has been
determined using nitrocefin as a chromogenic β-lactam substrate. For CTX-M-14 and KPC-2, two
buffers have been used of which the reaction buffer contains 100mM Tris-HCl, pH 7.0 and 0.01%
Triton X-100. Protein has been diluted using a protein solution buffer contain 100 mM Tris, pH
7.0, 200 mM Sodium Chloride and 0.002% Triton X-100. Steady state kinetic parameters e.g. Km,
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Kcat, IC50 values has been determined through monitoring nitrocefin hydrolysis rate using a
BioTek Synergy Mx monochromator-based multimode microplate reader at 486 nm wavelength
and by analyzing them through SigmaPlot program using Michaelis-Menten equation. For NDM1, the reaction buffer is composed of 50mM HEPES pH7.2, 50µM ZnSO 4 , 1 µg/mL bovine serum
albumin (BSA) and 0.001% Triton X-100. In case of OXA-48, the reaction buffer as well as the
protein solution buffer contains 100 mM Tris- H 2 SO 4 pH-7.0, 50 mM NaHCO3, 0.01% Triton X100. During IC50 determination for selected compounds, the substrate nitrocefin concentration for
CTXM-14, KPC-2, NDM-1 and OXA-48 used was 20µM, 10µM and 40µM whereas the final
concentration of these proteins used was 0.5 nM, 0.3 nM, 6 nM and 0.5 nM respectively.
Concentration of compounds have been utilized up to 5 mM based on their solubility in reaction
buffer to determine the corresponding IC50 values. Proteins were added last onto the reaction. To
calculate the binding affinity Ki value, Km value for nitrocefin substrate for the corresponding
CTX-M-14, KPC-2, NDM-1 and OXA-48 β-lactamases used was about 22 µM, 10µM, 3µM and
45µM etc.
5.5.4 Crystallization and soaking experiments
CTX-M-14, KPC-2 and NDM-1were crystallized as described previously. For both CTX-M-14
and KPC-2, crystals were soaked in 1.44 M sodium citrate containing 10 mM inhibitor for
approximately 2-24 hr. Crystals were then cryoprotected in a solution containing 1.15 M sodium
citrate, 20% (v/v) glycerol and flash-frozen in liquid nitrogen. To get protein ligand complex
structures, NDM-1 crystals were soaked in a solution of 50 mM sodium acetate pH 3.85, 25%
(w/v) PEG8000 and 10 mM inhibitor for 1-2 h. The soaked crystals were cryo-protected in a
solution containing 50 mM sodium acetate pH 7.50, 25% (w/v) PEG8000, and 20% (v/v) glycerol
and flash-frozen in liquid nitrogen. OXA-48 crystals were grown in a crystallization condition
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containing 200 mM Ammonium Acetate, 100 mM Sodium Acetate pH 4.6, 305(w/v) PEG-4000.
To obtain ligand bound structure for OXA-48, soaking condition containing 100 mM Sodium
Cacodylate pH 6.5, 40% (v/v) MPD, 5% (w/v) PEG 8000, 10 mM ligand have been used.
5.5.5 Data collection and structure determinations
Diffraction Data for the CTX-M-14, KPC-2, NDM-1, and OXA-48 complex structures were
collected using beamlines SBC-19-BM, SBC-19-ID, 22-ID-D and 23-ID-D at the Advanced
Photon Source (APS), Argonne, Illinois. Data indexing, integration and scaling was performed
through HKL-2000 and HKL-3000. Phasing was performed using molecular replacement with the
program Phaser of the Phenix suite, with the CTX-M-14 structure (PDB code: 1YLT) KPC-2
(PDB ID code: 3C5A), NDM-1 (PDB ID code: 4TYF), and OXA-48 (PDB ID code: 3HBR). To
perform structure refinement and model building phenix.refine program from Phenix suite and
WinCoot has been used. Before ligand modeling and refinement, the unbiased Fo-Fc electron
density maps for the ligand has been generated. Ligand geometry coordinates as well as restraints
file have been obtained using the program eLBOW in Phenix. The final model qualities of the
protein ligand complex structure have been evaluated through MolProbity program. To generate
figures, PyMOL 1.3 (Schrödinger) program has been utilized.
5.6 Note to Reader #1
The fragment library was obtained from our collaborator from UCSF. The Surface Plasmon
Resonance (SPR) studies have also been performed by Kyle Defrees from Dr. Renslo Lab from
UCSF.
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CTX-M-14 (1.40Å)

KPC-2 (1.65Å)

NDM-1(1.15Å)

OXA-48 (2.3Å)

Figure 5.1: Complex structure of Compound 1 in the active site of KPC-2 (A), CTX-M-14
(B), NDM-1(C) and OXA-48 (D). Fo-Fc map is colored in gray and contoured at 2 σ. Protein
residues are colored in green and compound 1 is colored in yellow. Zinc atoms for NDM-1 is
represented as gray sphere.
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Figure 5.2: Complex structure of Compound 7 in the active site of NDM-1 (A) and CTX-M14 (B). Fo-Fc map is colored in gray and contoured at 2 σ. Protein residues are colored in white
and compound 7 is colored in green. Zinc atoms for NDM-1 is represented as gray sphere.
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Figure 5.3: Complex structure of Compound 5 (A) and 6 (B) in the active site of NDM-1.
Fo-Fc map is colored in gray and contoured at 2 σ. Protein residues are colored in white and
compound 5 and 6 are colored in green. Zinc atoms for NDM-1 is represented as gray sphere.
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Figure 5.4: Complex structure of Compound 9 in the active site of KPC-2. Fo-Fc map is
colored in gray and contoured at 2 σ. Protein residues are colored in green. Conformation A
and Conformation B for compound 9 is colored in yellow and blue.
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Thr209
Ser70
Lys208
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Figure 5.5: Complex structure of Compound 16 with OXA-48. Fo-Fc map is colored in
gray and contoured at 2 σ. Protein residues are colored in green. Compound 9 is colored in
blue.
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Table 5.1. Nitrocefin inhibition assay for compounds obtained from Molecular Docking
tested against CTX-M-14, KPC-2, NDM-1 and OXA-48
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Table 5.2. Nitrocefin inhibition assay for compounds obtained from Surface Plasmon
Screening tested against CTX-M-14, KPC-2, NDM-1 and OXA-48
Structure
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Chapter 6: Summary

Carbapenemases represent the most versatile family of β-lactamases which encompasses most of
class A and D serine β-lactamases and all class B MBLs. Production of these enzymes is the most
prevalent mechanism used by gram-negative bacteria to become resistance against most of the βlactam antibiotics including carbapenem, the last resort available to clinicians. There are a very
few studies focused on understanding the premise of these enzyme’s unique structural and
mechanistic consideration responsible for their carbapenemase activity.
To investigate the difference in ligand binding characteristics between KPC-2 serine
carbapenemase and CTX-M-14 ESBL, we have performed SAR studies through utilizing both
biochemical and structural information about tetrazole based small molecules and the product
inhibition properties. We found out that the increased hydrophobicity and flexibility surrounding
the active site of KPC-2 makes it suitable to establish interactions with substrates and small
molecule ligands which is also more prominent in NDM-1. Differences in the side chain residues
between CTX-M-14 and KPC-2 including substitutions at N104P, Y105W and P167L as well as
flexibility in the side chain of W105 makes KPC-2 active site more open and hydrophobic. In case
of NDM-1, plasticity in the L3 loop close to the active site and the presence of hydrophobic
residues e.g. Leu65, Met67, Phe70 and Val73 in this loop enables it to accommodate a wide range
of substrates. This led us to conclude that the increased active site druggability of carbapenemase
is associated with their increased hydrophobicity and flexibility. This structural information can
be exploited for future antibiotic development against these clinically important group of enzymes.
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Although the tetrazole compounds mentioned in this study don’t have enough potency to denote
them as drug per se. however, amido-tetrazole compounds showed moderate activity against both
KPC-2 and NDM-1 and they bind to the substrate carboxylate binding site including accessory
binding hotspots which might facilitate further lead identification and optimization.
Development of non β-lactam based inhibitors targeting β-lactamase in a non-covalent
mechanism is a recent approach to resist MDR bacterial strains. Noncovalent inhibitors can be
exploited to perform chemical space sampling to identify the potential binding hotspots present in
the targeted active site. In this study, we have identified and optimized a heteroaryl phosphonate
scaffold to improve its potency against both serine and metallo carbapenemases using structurebased drug design, synthetic chemistry and X-ray crystallography approach. The most potent dibromo substituent DHQ analog (compound 16) showed 20 nM affinity towards KPC-2 which is
the highest affinity non-covalent inhibitors against any serine carbpenemase to date. This
compound also exhibited ~400 nM and 31 µM affinity against both VIM-2 and NDM-1 MBLs.
Microbiological assessment of compound 16 denoted its potential cell-based activity against
clinically relevant and laboratory strains of K. pneumoniae and P. aeruginosa. Complex structures
of NDM-1 and VIM-2 with these analogs at low (pH 4.6) and physiological pH (pH 7.5) revealed
the difference in the ionic state of the phosphonate group as well as their binding in the active site
of MBLs. Cytotoxicity assay showed that compound 16 was cytotoxic at or above 100 µg/ml when
tested against human HEK-293 cells. In future, we plan to optimize this scaffold to improve its
potency against NDM-1 while retaining its activity against KPC-2. Ultimately, we hope to utilize
this SAR studies for the heteroaryl phosphonate scaffold as a suitable alternative for further
inhibitor discovery efforts.
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Fragment based drug discovery is a recently emerged technique in the field of medicinal chemistry
where fragments or low molecular weight compounds which interacts with the subsite of the target
have been identified and then linked together to get higher affinity lead like molecules. In our
study, we have performed both virtual and biophysical screening of fragments targeting multiple
classes of β-lactamases using Molecular Docking and SPR as a primary screening method.
Fragments were then prioritized for secondary screening using a β-lactamase assay. Complex
structures were obtained for some of the tetrazole and phosphonate-based fragments with CTXM-14, KPC-2, NDM-1 and OXA-48. For most of the fragments, the biochemical affinity stayed
between low µM to mM in range. We hope to further optimize these fragments to improve their
potency as well cell-based activity.
Since after the identification of OXA-48 type CHDLs, there were no studies observed to
understand the molecular basis of its unique substrate specificity and carbapenemase activity.
Using X-ray crystallography, we have obtained acyl-enzyme complex structure with meropenem,
imipenem, faropenem and cephalosporins e.g. cefotaxime and cefoxitin and a product complex
structure with imipenem. For hydrolyzed imipenem, the newly generated carboxylate group
retained in the active site and formed hydrogen bond with carbamate group of Lys73. Comparison
of imipenem acyl enzyme complex with the product complex exhibited significant rotation of
hydroxyethyl group of imipenem which is also accompanied by conformational changes of the
active site residues. Difference in pyrroline and dihydrothiazine ring tautomerization has been
noticed among acyl enzyme as well as product complex structures which might be due to
difference in the chemical structures of meropenem, imipenem and faropenem. In case of
imipenem, the pyrroline ring at C1 position is unsubstituted which might allow the rotation of
hydroxyethyl group to facilitate the activation and positioning of the hydrolytic water molecule.
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However, both meropenem and faropenem has methyl and sulfur substitutions at C1 position of
the pyrroline ring which might hinder the rotation of the substrate hydroxyethyl group as well as
the deacylation step. This information would facilitate us to reveal the molecular basis of OXA48 substrate specificity and carbapenemase activity which will further aid in inhibitor discovery.
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